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Conjugated linoleic acid (CLA) is a collective term for a group of geometric and 
positional isomers of linoleic acid (LA) in which the double bonds are conjugated. 
A range of beneficial effects of CLA has been described. The present study was to 
examine the antioxidant and hypolipidemic activities of CLA. A strong antioxidant 
activity of CLA has been exhibited on the copper-induced oxidation of human low 
density lipoprotein (LDL) in vitro. The protective effect of CLA on LDL oxidation 
was in a dose-dependent manner with the concentration ranging from 2.5 to 20 mM, 
while LA showed an pro-oxidant effect on LDL oxidation. Most probably, the 
antioxidant effect was due to the transformation of conjugated diene to a P-hydroxy 
acrolein moiety. 
By using golden Syrian hamsters as an animal model, the hypolipidemic effect 
of CLA was examined. Animals were fed a high-fat and high-cholesterol semi-
synthetic diet with or without 2% LA or 2% CLA supplementation. By 8 weeks 
serum total cholesterol (TC) and triglycerides (TG) were significantly lowered in the 
LA-supplemented and CLA-supplemented groups, but no effect on high density 
lipoprotein (HDL) cholesterol was observed. The ratio of serum TC to HDL-
cholesterol ratio was significantly reduced in the CLA-fed hamsters. A distinct 
lowering effect ofhepatic cholesterol was found in the CLA-supplemented group. 
The possible mechanisms by which CLA supplementation decreased the serum 
and hepatic cholesterol were studied. CLA supplementation exhibited a neutral 
effect on hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
activity, the rate-limiting enzyme in cholesterol synthesis. However, intestinal acyl 
coenzyme A: cholesterol acyltransferase (ACAT) activity was down-regulated up to 
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58% by dietary CLA supplementation. ACAT is a critical enzyme in cholesterol 
esterification and absorption. CLA supplementation increased the fecal excretion of 
fecal neutral sterols, but it had no effect on the fecal excretion of acidic sterols. 
The present results suggested that CLA is antiatherogenic not only because of 
its hypolipidemic effect, but also its in vitro antioxidant activity. The hypolipidemic 
effect of CLA is most probably due to the inhibition of cholesterol absorption via 
down-regulation of intestinal ACAT activity and increasing the fecal excretion of 







在2.5 mM-20 mM濃度範圍內呈量效關係�在同樣的實驗中，亞油酸則展現量 
效的促氧化作用。亞油酸不但不能保護低密度脂蛋白抵抗氧化，反之促進其氧 
化過程。有關共_亞油酸抗氧化作用的機制，也許跟它的共軛雙鍵結構有關； 

























ACAT Acyl coenzyme A: cholesterol acyltransferase 
ANOVA Analysis of variance 
Apo Apolipoprotein 
BHT Butylated hydroxytoluene 
BSA Bovine serum albumin 
CHD Coronary heart disease 
CLA Conjugated linoleic acid 
DMBA 7, 12-dimethyl-benz[a]anthracene 
FAME Fatty acid methyl ester 
GLC Gas liquid chromatography 
HDL High density lipoprotein 
HMG-CoA 3 -hydroxy-3 -methyglutaryl conenzyme A 




LA Linoleic acid 
LDL Low density lipoprotein 
MCP-1 Monocyte chemoattractant protein 
MDA Malondialdehyde 
Mm-LDL Minimally modified LDL 
Ox-LDL Oxidatively modified LDL 
PL Phospholipid 
PLPC 1 -palmitoyl-2-linoleyl phosphatidylcholine 
PUFAs Polyunsaturated fatty acids 
SD Standard deviation 
TBARS Thiobarbituric acid reactive substances 
TC Total cholesterol 
TCA Trichloroacetic acid 
TG Triglyceride 
TLC Thin layer chromatography 
TMS Trimelhylsilyl 
TPA 12-0-tctradecanoyl-phrobol- 13-acetate 
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Conjugated linoleic acid (CLA) is a group of geometric and positional isomers 
of the conjugated dienes of linoleic acid (LA). LA, cis-9, cis-12-octadecadienoic 
acid, is an essential dietary fatty acid found mainly in plant oils. Different from 
those in LA, the double bonds in CLA are conjugated instead of being in the typical 
methylene interrupted configuration. The positions of the two double bonds in 
CLA can be in one of the following combinations, 7 and 9, 8 and 10, 9 and 11, 10 
and 12, 11 and 13, or 12 and 14 along the 18-carbon chain (Christie et al., 1997; 
Sehat et al., 1998a; Sehat et al., 1998b; Yurawecz et al., 1998). Each ofthe double 
bonds can be either in cis or trans configuration. Schematic structures of cis-9, 
trans-11 - and trans-lO, cis-12-CLA isomers, the most predominant two isomeric 
forms in nature, are shown in Figure 1.1. CLA can be found in a wide variety of 
foods, but it is abundant mainly in ruminant animal products and dairy products 
(Chin et aL, 1992). It is also found that CLA has several important biological 
activities including anticarcinogenesis, antiatherogenesis, enhancement of immune 
responses and alteration ofbody composition (Haumann, 1996; Steunhart, 1996). 
1.2 Formation ofCLA 
The conjugated diene structure is not usual in fatty acids, though the existence 
of CLA has been known for many years. As early as 1950s, a number of studies 
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Figure 1.1 Structures oft-10, c-12-CLA (top), c-9, t-ll-CLA (center), LA (bottom). 
The molecules are aligned at their carboxyl end to show the influence of double 
bonds on molecular shape, (adapted from Steinhart, 1996) 
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showed the presence ofCLA in ruminants. Until 1960s, it was found that CLA was 
formed in rumen of ruminant animals by the anaerobic rumen bacterium, namely 
Butyrivihrio fibrisolvens (Kepler et al., 1965). Through the biohydrogenation of 
LA, the cis-l2 bond of free LA is converted to a trans-ll bond, resulting in the 
formation of CLA. The reaction is catalyzed by an enzyme, namely, linoleate 
isomerase, and the cis-9, trans-U-CLA isomer is the first intermediate in the reaction 
(Figure 1.2). CLA can also be produced in non-ruminant by intestinal bacterial 
flora and 9, 11-isomer is the predominant form, but this is not applicable in humans 
(Chin et al,, 1994; Herbel et al., 1998). However, CLA has been identified to be 
present in human body fluid such as serum, bile, duodenal juice and human milk 
(Cawood et aL, 1983; Iversen et al., 1984; Thompson & Smith, 1985; McGuire et aL, 
1997). Most probably, it is due to the uptake of CLA from daily diet. 
CLA can also be prepared chemically. Conventional methods include 
biohydrogenation (Kepler & Tove, 1967; Hughes et al., 1982) and alkali 
isomerization of LA (Nichols et al., 1951). However, a mixture of different CLA 
isomers is produced by these methods. In order to study individual CLA isomer, 
other methods are developed recently. For example, trans-lO, cis-l2- and cis-9, 
tmns-ll-CLA isomers can be prepared from LA (Berdeaux et al,, 1998). Moreover, 
pure cis-9, trans-W-CLA isomer can be produced by dehydration of ricinoleate (12-
hydroxyoctadec-cis-9-enoate) of caster oil (Berdeaux et al., 1997; Jie et al., 1997), or 
by the reduction of ximenynate (11 -trans-octadecen-9-ynate) of Santalum album seed 
oil (Aldof, 1999). 
3 
H H H H 
I I I I 
CH (CH )-C-C=C-C-C-(CH ) COOH 
3 24 I I I I 27 
H H H H 
+ 
H H H H 
I I I I 
CH (CH )-C-C-C-C=C-(CH ) COOH 
3 24 I I I I 27 
H H H H 
Figure 1.2 Proposed pathway for biohydrogenation of linoleic acid (LA) by 
Butyrivibrio fibrisolvens. Cis-9, trans-11-octadecadieonic acid is the intermediate 
in the pathway. (adapted from Kepler et al., 1966) 
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1.3 Occurrence of CLA in Foods 
CLA is present in variety of foods, but predominantly in ruminant and dairy 
products (Parodi, 1977; Chin et al., 1992). This is due to the microbial 
biohydrogenation of LA in the ruminant rumen. The levels of CLA in various 
foods have been reported to vary from as low as 0.2 mg / g fat in com oil and peanut 
oil to as high as 4.3 mg / g in beef, 5.45 mg / g in Swiss cheese and 6.39 mg /g in 
evaporated milk, of which cis-9, trans-ll-isomQV accounts up to 90 % of the total 
CLA (Table 1.1 & 1.2). Negligible amounts have been observed in vegetable oil 
and seafoods including salmon and mussels (Chin et aL, 1992; Lin et al., 1995). 
The variation in CLA content is primarily due to the differences in the 
production processes. These include temperature, protein quality, and choice of 
starter culture and addition of whey protein during fermentation for dairy products 
(Ha et al,, 1989; Chin et al., 1992; Jiang et al., 1998; 0'Shea et al., 1998; Lin et al., 
1999). For the dairy and meat products, a number of factors including diet, feeding 
regimen, animal breed and seasonal influences would also affect the level of CLA 
(0'Shea et al., 1998). For example, diet restriction, holding with ecological 
farming, or feeding with fresh pasture rich of polyunsaturates in lactating cows can 
remarkably increase total CLA and cis-9, ^n27ts-ll-isomer content in bovine milk 
(Jiang et al., 1996; Jahreis et al., 1997; Precht & Molkentin, 1997; Kelly et al., 1998; 
Loor & Herbein, 1998; Dhiman et al., 1999). 
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Table 1.1 CLA content in uncooked meats and seafoods. 
Food stuff Total CLA (mg/g fat)^ c-9, M l (%)' 
Ruminant Meat 
Fresh ground beef 4.30 士 0.13 85 
Veal 2.70 士 0.24 84 
Lamb 5.60 士 0.29 92 
Beefsmoked sausage 3.80±0.07 84 
Comed beef 6.60 土 0.08 85 
Non-ruminant meat 
Pork 0.60 士 0.06 82 
Chicken 0.90 士 0.02 84 
Fresh ground turkey 2.50 土 0.04 76 
Egg yolk 0.60 士 0.05 82 
Sea food 
Salmon 0.30 土 0.05 n.d.' 
Lake trout 0.50 土 0.05 n.d. 
Sea scallops 0.30 士 0.05 n.d. 
Shrimp 0.60±0.10 n.d. 
Mussels 0.40 士 0.04 n.d. 
1 Values are means 土 standard deviation 
2 Values are expressed as % of total CLA isomers 
3 n.d. = not detectable 
(adapted from Chin et al,, 1992) 
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Table 1.2 CLA content in dairy products and oils.  
Food stuff Total CLA (mg/g fat)^ c-9, M l (%)' 
Milk product 
Homogenized milk 5.50 士 0.30 92 
Condensed milk 7.00 ± 0.29 82 
Butter fat 6.10土0.21 89 
Ice cream 3.60±0.10 86 
Custard style yogurt 4.80 士 0.16 83 
Natural cheese 
Blue 5.70土0.18 90 
Mozzarella 4.90 士 0.20 95 
Reduced fat Swiss 6.70 士 0.56 90 
Cheddar-medium 4.10 士 0.14 80 
Processed cheese 
American processed 5.00±0.13 93 
Cheez whiz™ 5.00±0.07 92 
Old English spread^^ 4.50 士 0.21 88 
Plant oil 
Safflower 0.70±0.14 44 
Sunflower 0.40i0.02 38 
Peanut 0.20±0.01 46 
Canola 0.50 士 0.07 44 
Com 0.20 士 0.03 39 
Coconut 0.10±0.01 47 
Olive 0.20±0.01 47 
1 Values are means 士 standard deviation 
2 Values are expressed as % of total CLA isomers 
3 n.d. = not detectable 
(adapted from Chin et aL, 1992) 
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1.4 Physiological Effects of CLA 
In the late of 1970s, CLA was isolated and identified serendipitously in an 
investigation of possible mutagens in grilled ground beef. Surprisingly, CLA was 
able to consistently modulate mutagenesis in the Ames {Salomonella) test and 
frequently show an antimutagenic activity (Steinhart, 1996). After that, numerous 
studies are taken to reveal its astonishing range ofbiological effects. 
1.4.1 Anticarcinogenic Effects of CLA 
After its discovery, CLA has been studied intensively for its anticarcinogenic 
property. Numerous studies have shown that CLA is a potent anticarcinogen. 
Moreover, the National Academy of Sciences (USA) has already pointed out that 
CLA is the only fatty acid, which unequivocally inhibits carcinogenesis in 
experimental animals (National Research Council, 1996). 
In the earliest studies, synthetic CLA was tested for anticarcinogenic activity in 
mice and Sprague-Dawley rats using epidermal, forestomach and mammary 
carcinogenesis models, with 7, 12-dimethyl-benz[a]anthracene (DMBA) as the 
initiating carcinogen (Ha et aL, 1987 & 1990; Ip et al., 1991). Subsequent in vitro 
and in vivo animal studies have confirmed that CLA could delay or reduce the onset 
of human cancer cell-lines and chemically-induced tumors in various sites, including 
mammary glands, prostate glands, colon, skin and stomach (Shultz et al., 1992; Ip et 
aL, 1994; Thompson et al., 1997; Visonneau et al,, 1997; Wong et al., 1997; Cesano 
et al., 1998; 0'Shea et al., 1998). Biomarkers of carcinogenesis that have been 
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shown to be influenced by CLA are listed in Table 1.3. 
There are many proposed mechanisms for the anticarcinogenic effect of CLA. 
Various studies suggest that CLA may be beneficial by enhancement of immune 
response, antioxidant activity, pro-oxidant cytotoxicity, inhibition of nucleotide and 
protein synthesis, inhibition of both DNA-adduct formation and carcinogen 
activation, reduction of proliferative activity, interference in oestrogen-regulated 
mitogenic pathway, and decreased production of growth stimulatory eicosanoids via 
the inhibition of arachidonic acid synthesis pathway (Belury, 1995; Durgam & 
Femandes, 1997; Parodi, 1997; 0'Shea et al., 1998). In deed, Liu and Belury (1998) 
had shown that CLA could decrease 12-0-tetradecanoyl-phorbol-13 -acetate (TPA)-
induced tumor promotion in mouse skin and reduce the level of arachidonic acid and 
prostaglandin E: levels. Most probably, CLA may compete with LA for the 
metabolic enzymes such as A6-desaturase and elongase, resulting in the reduction of 
arachidonic acid level. As a result, eicosanoid synthesis is down-regulated and 
prostaglandin level is also decreased. Eicosanoids are usually associated with the 
proliferation of cancer cells. More recently, it is proven that CLA inhibits 
mammary cancer in rats via reducing in DNA synthesis and a stimulation of 
apoptosis (Ip et al., 1999). Therefore, CLA may exert its anticarcinogenic effect in 
multiple ways. 
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Table 1.3 Biomarkers of carcinogenesis shown to be influenced by CLA 
Biomarkers 
> Incidence, number and size of tumors in experimental models 
> Ornithine decarboxylase induction 
> Growth and proliferation of cancer cell lines 
——M21-HPB. Malignant melanoma 
— H T - 2 9 , colorectal 
— M C F - 7 breast 
— A - 4 2 7 , SK-LU-1, A549 lung adenocarcinoma 
——7800NJ rat hepatoma 
> Bromodeoxyuridine incorporation by rat mammary epithelial cells 
> Cytochrome P450 isozymes responsible for carcinogen activation, 
2-amino-3-methylimidazole[4,5f]quinoline (IQ) 
> Level of IQ-DNA adducts in liver, lung, large intestine, kidney 
(adapted from 0'Shea et al., 1998) 
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1.4.2 Antiatherogenic Effect of CLA 
A number of studies have suggested the inverse relationship between dietary 
CLA and the risk of atherogenesis. Lee et al. (1994) reported that feeding CLA 
could significantly lower semm total cholesterol (TC), low-density lipoprotein (LDL) 
cholesterol and triglycerides (TG) in rabbits. The risk factors for atherosclerosis, 
including the ratio of LDL cholesterol to HDL cholesterol and the ratio of total 
cholesterol to HDL cholesterol, were also significantly reduced. In addition, CLA 
could effectively reduce the occurrence, including number and volume, of cholesterol 
plaque in thoracic and abdominal aorta. Similar observations were also 
demonstrated in hamsters. From the study of Nicolosi et al. (1997), dietary CLA 
exhibited hypolipidemic effects and reduce the aortic fatty streak formation, the 
initial event of early atherosclerosis. Moreover, the ratio of plasma tocopherol to 
TC was elevated, suggesting a tocopherol-sparing effect by CLA treatment. 
Furthermore, from a more recent in vitro study, trans-lO, cis-l2-CLA isomer was 
able to reduce apolipoprotein B (apoB) secretion, and suppress TG and cholesteryl 
ester synthesis in human HepG2 cell-line (Yotsumoto et al., 1999). ApoB is an 
important component of very low-density lipoprotein (VLDL) and LDL, and plays a 
crucial role in atherogenesis. An increased blood apoB level is an independent risk 
factor for coronary heart disease. 
However, an opposed observation was reported by Munday et al. (1999). 
They found that dietary CLA might promote aortic fatty streaks formation in mice, 
even though semm TG and TC levels were lowered by CLA. 
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1.4.3 Antioxidant Effect of CLA 
It is still controversial whether CLA may act as an antioxidant. Unlike other 
antioxidants (e.g. phenolic compounds, camosine and pyrroloquinoline quinone), 
CLA per se has nothing in structure like tautomeric form or functional groups, which 
possess antioxidant activity (Decker, 1995; Yurawecz et al., 1995). However, from 
the study of Ha et al. (1990), CLA was found as a good antioxidant. It was more 
potent than a-tocopherol and almost as effective as butylated hydroxytoluene (BHT), 
a synthetic antioxidant widely used as a food preservative. The proposed 
mechanism involves the transformation of the conjugated dienoic functional group to 
a P"hydroxy acrolein moiety. Therefore, the antioxidant activity is due to the 
oxidized derivative of CLA instead of the original forms. Ip et al. (1991) also 
reported that CLA could suppress lipid peroxidation of unsaturated fatty acids in the 
range from 0.25 % to 1.5 % CLA. Moreover, it is proposed that the 
anticarcinogenic effect of CLA is, at least partially, due to its antioxidant activity. 
However, several recent studies disagreed with that CLA was an antioxidant. 
From the study of van den Berg et al. (1995), CLA neither acted as an efficient free 
radical scavenger nor a metal chelator. CLA could not protect membranes 
composed of 1 -palmitoyl-2-linoleyl phosphatidylcholine (PLPC) from oxidative 
modification under metal ion-dependent or independent oxidative stress. 
Furthermore, CLA was found as a pro-oxidant and able to accelerate lipid oxidation 
in canola oil. CLA was oxidized much faster than LA in air, and the conjugated 
double bonds were more susceptible to oxidation than non-conjugated double bonds 
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(Chen etal., 1997). 
The discrepancy of these studies is probably due to different experimental 
conditions and assay systems used. For example, a phosphate buffer system 
containing 40 % ethanol was used in the study of Ha et al. (1990). On the other 
hand, a buffering system with methanol was used by van den Berg et al. (1995). 
Nevertheless, such systems are far from the biological system, and further 
investigations are necessary on the antioxidant property of CLA. 
1.4.4 CLA and Immune Response 
CLA is not toxic, even under high dose-treatment (Scimeca, 1998). On the 
contrary, treatment with CLA may enhance immune response. Many studies have 
shown the immuno-stimulating effect of CLA. Treatment with CLA can enhance 
proliferation of lymphocyte and production of interleukin-2 (IL-2), but it does not 
have any effect on lymphocyte cytotoxicity (Michal et al., 1992; Wong et aL, 1997; 
Michael et al., 1999). The most accepted hypothesis is the fatty acid modulation of 
membrane fluidity by CLA supplementation, resulting in changing the signal 
transduction and cell cycle induction mediated by cell membrane. Thus, the 
efficacy of the lymphocyte in antigen recognition is increased and receptor-ligand 
interaction is improved (Wong et al,, 1997). Another hypothesis is that CLA may 
decrease the conversion of LA to arachidonic acid which is the precursor of 
prostaglandins. Decrease in prostaglandins is known to suppress lymphocyte 
function, and, therefore, immune function (Wong et al., 1997). 
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CLA may also diminish food allergy. From the finding of Sugano et al (1998), 
dietary CLA could mitigate food allergic reaction by inducing the release of 
immunoglobulin (Ig) A, IgG and IgM, and decreasing the level of IgE in rats. IgA 
and IgG can serve as antiallergic factors by interfering the intestinal absorption of 
allergen, and by competing the binding sites of allergen to the receptor on the surface 
of the target cells (mast cells and basophiles) respectively. In contrast, IgE is 
allergen-specific. It triggers the release of chemical mediator, including histamine, 
leukotriene (LT) and prostaglandin, which are involved in food allergic reaction. 
CLA also suppresses weight loss mediated by immune system. Miller at al 
(1994) found that CLA feeding could apparently prevent severe weight loss induced 
by endotoxin injection in mice. Endotoxin can induce weight loss by inducing 
anorexia and suppressing growth. 
1.4.5 CLA and Body Composition 
One of the reasons making CLA attractive is its effect on body composition. 
Dietary CLA can efficiently reduce body fat, meanwhile it can increase whole body 
lean mass. Several of studies have shown CLA feeding can produce a rapid, 
marked decrease in fat accumulation , and an increase in protein accumulation, at 
relatively low dose without any major side effect on food intake in mice and rats 
(Belury & Kempa-&eczko, 1997; Park et al., 1997 & 1999; West et al., 1998; 
Delany et al., 1999). For example, in the study of Delany et al. (1999), feeding 
with 0.25 % to 1.0 % CLA could significantly reduce the weight of inguinal, 
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epididymal，retropeitoneal and nesenteric adipose tissues. Also, the body fat 
percentage was markedly decreased, while the body protein percentage was 
increased. In another study, feeding with CLA could decrease absolute whole body 
fat, and increase relative whole body protein, water and ash (Park et aL, 1999). 
Increase in energy expenditure and fat oxidation is the possible explanation for 
body fat reduction by CLA. It has been reported that CLA could produce a dose-
dependent reduction in lipoprotein lipase activity in cultured adipocytes. 
Lipoprotein lipase is responsible for the hydrolysis of fatty acids from circulating TG, 
and the free fatty acids are then taken up by the adipocytes and re-esterified. 
Moreover, CLA could induce lipolysis by elevating carnitine palmitoyltransferase 
activity in skeletal muscle. Carnitine palmitoyltransferase is the rate-limiting 
enzyme in fatty acid P-oxidation (Park et al,, 1997). CLA is also able to inhibit 
adipocyte hypertrophy and preadipocyte hyperplasia (Brodie et al, 1998; Satory & 
Smith, 1998). However, there is still no evidence to explain for the protein 
accumulation by CLA. Possibly, it may be due to the elevated level of plasma 
insulin and stimulation of growth hormone secretion by CLA (Delany et al., 1999). 
CLA may also alter the body fatty acid composition. Under CLA 
supplementation, different isomers can be incorporated into different tissue lipid 
classes in mice, pig and human. Among these isomers incorporated, cis-9, trans-
11-CLA isomer is the predominant form (Belury & Kempa-Steczko, 1997; Kramer et 
al., 1998; Jiang et al., 1999). Lee et al. (1998) demonstrated that CLA could alter 
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the hepatic membrane fatty acid composition by decreasing hepatic stearoyl-CoA 
desaturase mRNA expression. Stearoyl-CoA desaturase is a key enzyme involved 




Protective effect of CLA on 
Copper-Induced Human LDL oxidation 
2.1 Introduction 
Low-density lipoprotein (LDL) is the major cholesterol carrier in blood. The 
function of LDL is to transfer cholesterol to peripheral tissues and regulate de novo 
cholesterol synthesis at these sites. LDL is up-taken by LDL receptors, which are 
located on the surface of cells, through receptor-mediated endocytosis (Fig. 2.1). 
The internalized LDL is delivered to lysosomes where its cholesteryl esters are 
hydrolyzed, and the liberated cholesterol is used by the cell for different purposes. 
The number of LDL receptors and endocytosis of LDL are tightly regulated by the 
intracellular cholesterol level via feedback mechanism (Brown & Goldstein, 1986). 
/ I 
An elevated level of LDL in the circulation is one of the major risk factors for 
atherosclerosis, featured with intimal thickening, loss of elasticity of arterial wall, 
obstruction of artery and formation of atherosclerotic plaques (Fig. 2.2) (Goldstein & 
Brown, 1977). Moreover, oxidatively modified form ofLDL (ox-LDL) is believed 
to play the key role in the development and subsequent events of atherosclerosis 
(Steinberg, 1997). 
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Figure 2.1 Sequential steps in the LDL receptor pathway of mammalian cells. 
HMG CoA reductase, 3-hydroxy-3-methylglutaryl CoA reductase; ACAT, acyl-CoA: 
cholesterol acyltransferase. Vertical arrows indicate the directions of regulatory 
effect, (adapted from Brown and Goldstein, 1986) 
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Figure 2.2 An atherosclerotic plaque (marked by the arrow) blocks most of the 
lumen of blood vessel. The plaque is rich in cholesterol. (adapted from 
Biochemistry/Lubert Stryer~4^ ed.) -
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2.1.1 Oxidative Modification of LDL and Atherosclerosis 
2.1.1.1 Understanding LDL 
Human LDL is derived from very low density lipoprotein (VLDL) via a 
lipoprotein known as intermediate-density lipoprotein (IDL). It is small enough 
(180-250 A in diameter) to penetrate the vascular endothelium and enter tissue fluid, 
and responsible for transporting cholesterol from liver to other tissues. 
Human LDL is a spherical particle («2.5 MDa) with a density ranging 1.019-
1.063 kg / L (Esterbauer et al., 1992). The major protein component of LDL is 
apolipoprotein B-lOO (apoB-100), one of the largest known proteins with 4,536 
amino acids and 514 kDa (Knott, et al., 1986). Each LDL particle contains 
approximately 22 % apoB-100, 22 % phospholipids (as the monolayer hydrophilic 
coat), 8 % cholesterol, 42 % cholesteryl esters, and 6 % TG (Orlova et al., 1999). 
2.1.1.2 Oxidative Modification of LDL 
There are numerous types of modification of LDL such as acetylation, 
acetoacetylation, conjugated with malondialdehyde, oxidative modification (Sparrow 
et aL, 1988a) and covalently bonded with apo(a) (Nielsen, 1999). 
The mechanism by which LDL becomes oxidized in vivo is still unclear. 
Various studies implicate that free radicals and reactive oxygen species, such as 
superoxide anions mediated by smooth muscle cells and phagocytes, are able to 
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initiate the self-propagating chain reactions in native LDL and lead to the production 
of oxidized LDL (Heincke et al., 1986). 15-Lipoxygenase, a cellular enzyme 
present in macrophages and endothelial cells, is also able to convert polyunsaturated 
fatty acids (PUFAs) into lipid hydroperoxides which may oxidize LDL (Sparrow et 
al,, 1988b). Moreover, myeloperoxidase, a heme protein present in activated 
neutrophils and monocytes, can induce oxidation ofLDL. Hypochlorite and tyrosyl 
radical, the in vivo products of myeloperoxidase action, can catalyze the hypochlorite 
oxidation of apoB-100 and lipid peroxidation ofLDL respectively (Savenkova et aL, 
1994). Oxidation of LDL with hypochlorite causes transformation of lipoprotein 
into a high uptake form for macrophages (Hazell & Stocker, 1993). Nitric oxides 
and perinitrite are other oxidants relevant to LDL oxidation produced by endothelial 
cells and macrophages (Jialal & Devaraj, 1996). Glycoxidation reactions of glucose 
also play a role in LDL oxidation (Hamilton, 1997). 
In cell-free system, LDL can be oxidatively modified by divalent transition 
metal ions, usually iron and copper. These metal ions can lead to free radical 
formation and initiation of lipid peroxidation via the Fenton reaction (Hamilton, 
1997). LDL can be oxidized in a metal-independent system with 2, 2'-azobis(2-
amidinopropane) (AAPH). It is a water soluble azo compound and thermally 
decomposes, leading to the formation of aqueous peroxyl radicals at a constant rate 
(Frei et al., 1988). LDL can also be oxidized in vitro by all the major cells of the 
arterial wall, such as endothelial cells (Steinbrecher et al., 1984), smooth muscle 
cells, and monocytes-macrophages (Jialal & Devaraj, 1996). Sparrow et al. (1988b) 
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reported that purified soybean lipoxygenase could mimic endothelial cell-induced 
oxidative modification ofLDL, in the presence of phospholipase A�. 
Oxidation of LDL is a complex multi-step process. It results in profound 
alterations of both the lipid and protein components of LDL, including fragmentation 
of apoB-100, hydrolysis of phosphatidylcholine, and loss of esterified cholesterol 
(Steinbrecher, 1987). The initial event of LDL oxidation is the abstraction of a 
hydrogen atom from the fatty acid moiety by a reactive oxygen species, leaving an 
unpaired electron on the carbon atom. This leads to a molecular rearrangement of 
double bonds with the formation of conjugated dienes, which, in tum, react with 
oxygen to form lipid peroxy radicals (Eserbauer et al,, 1992). However, the 
presence of endogenous antioxidants (a-tocopherol, y-tocopherol and P-carotene) 
can delay the rate of oxidation, resulting in the lag phase of oxidation (Holvoet & 
Collen, 1998). ^After the depletion of endogenous antioxidants, the lipid peroxy 
radicals continue to propagate the reaction and abstract another hydrogen atom from 
other fatty acids, leading to the formation of lipid peroxides. Termination of the 
reaction is by interaction of one free radical with another (Hamilton, 1997). 
Actually, during oxidation, the fatty acids in LDL are decomposed and degraded 
constantly, resulting in cleavage of double bonds and formation of aldehydes. This 
heterogeneous group of unsaturated aldehydes can form adducts with the s-amino 
groups and neutralize the positive charge of lysine residues in apoB-100 
(Steinbrecher, 1987). All of these result in the increase of the negative net charge 
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and protein conformational change in the response to charge-modification of LDL 
particles (Haberland et aL, 1984). As a result, oxidatively modified LDL is no 
longer recognized by native LDL receptor (Brown & Goldstein, 1986), but taken up 
by monocyte/macrophages via the scavenger receptor pathway (Sparrow et al., 
1989). 
2.1.1.3 Role of Oxidatively Modified LDL in Atherogenesis 
Oxidized LDL (ox-LDL) plays a key role in the atherogenesis (Quinn et al,, 
1987; Jialal & Devaraj, 1996; Steinberg, 1997). A schematic depiction of the role 
of ox-LDL in atherogenesis is shown in Figure 2.3. In brief, native and minimally 
modified LDL (mm-LDL) present in the subendothelial space is oxidatively 
modified either by endothelial cells, smooth muscle cells, or macrophages, forming 
ox-LDL. Ox-LDL plays a dual role in atherogenesis. First, it inhibits motility of 
macrophages and thus the probability of exiting from the arterial wall. Second, it is 
chemotactic for the circulating monocytes (Quinn et al., 1987). Furthermore, ox-
LDL is taken up by monocyte/macrophages via the scavenger receptor pathway, 
which is not regulated by intracellular cholesterol content (Steinberg et al., 1989). 
In this way, because of the high uptake rate and high turnover rate of ox-LDL, 
macrophages are converted to foam cells. Also, ox-LDL is potentially cytotoxic to 
endothelial cells (Steinberg, 1997). Endothelial injury caused by ox-DL may 
further enhance the rate of LDL penetration into the arterial vessel, either through 
actual breaks in the lining monolayer or as a result of modification in trans-
endothelial cell transport function. 
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Figure 2.3 Role of oxidized LDL (ox-LDL) in atherogenesis. (adapted from 
Quinn etaL, 1987) 
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Additional atherogenic properties of ox-LDL have also been described. For 
example, ox-LDL is chemoattractant for T-cells, which comprise a proportion of the 
cells in atherosclerotic lesions (Steinberg, 1997). Moreover, ox-LDL stimulates the 
release of monocyte chemoattractant protein (MCP-1) from the endothelial cells. 
Thus, ox-LDL can exert both a direct and indirect effect on the recruitment of 
monocytes from the circulation (Berliner et al., 1995). 
Notwithstanding this, LDL buoyancy, including size and density, is also related 
to the risk of atherogenesis. Small and dense LDLs have been found to penetrate 
the arterial wall more readily than buoyant LDL and to be more easily oxidized in an 
oxidizing environment (Austin et al., 1988; Zambon et al., 1999) 
2.1.2 Antioxidants and Atherosclerosis 
Data are accumulating from both laboratory and epidemiological studies, 
supporting the link between dietary antioxidants and atherosclerotic disease. Indeed, 
a-tocopherol, y-tocopherol and p_carotene present in LDL particle act as endogenous 
natural antioxidants to protect LDL against oxidative modification (Holvoet & 
Collen, 1998). The Cambridge Heart Antioxidant Study (CHAOS) has also shown 
that supplementation of vitamin E (400-800 IU / day) could lead to a significant 
decrease in cardiovascular death and nonfatal infarction (Stephen et al., 1996). a-
Tocopherol (vitamin E) is the principal lipid-soluble antioxidant in plasma and in the 
LDL particle. It is a lipophilic chain-breaking antioxidant and traps peroxyl free 
radicals (Esterbauer et al,, 1990). a-Tocopherol inhibits free radical-mediated LDL 
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oxidation in vitro, and ascorbic acid (vitamin C) acts as a synergistic antioxidant in 
conjunction with a-tocopherol (Sato, 1990). 
Other hypocholesterolemic agents, like probucol and pravastatin, could also 
reduce the rate of progression of atherosclerosis (Carew et al., 1987; Salonen et al., 
1995). Natural flavonoids, polyphenols in red wine and catechins in tea, may also 
serve as sources of dietary antiatherogenic agent (Miura et al., 1995). 
However, some epidemiological studies did not prove the protective effect of 
antioxidant on atherogenesis. For example, Walldius et al. (1994) showed that 
dietary probucol did not show an inhibitory effect on femoral artery stenosis; in 
another two experiments, long-term supplementation with p-carotene or vitamin A 
had no reductive effect on cardiovascular disease (Hennekens et al., 1996; Omenn et 
al., 1996). 
2.1.3 Measuring TBARS Formation as an in vitro Index to Monitor LDL 
Oxidation 
Measurement of the thiobarbituric acid-reactive substances (TBARS) formation 
is an in vitro index for the lipid peroxidation. Though with arguments and limitations, 
measuring TBARS is still the most frequently used method. It can give relatively 
good sensitivity and reliable results with LDL in cell-present and cell-free systems 
(Puhl et al., 1994). During LDL oxidation, malondialdehyde (MDA), a highly 
reactive dialdehyde, is formed from the breakage of the conjugated diene or double 
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bonds of a PUFA in LDL, and assay of TBARS is an alternative way to monitor LDL 
oxidation by measuring the MDA formed. In this method, chromagen is formed by 
the reaction of one molecule of MDA and two molecules of TBA. The reaction 
involves heating the oxidized LDL sample with thiobarbituric acid (TBA) under 
acidic conditions, attained by addition of trichloroacetic acid (TCA) solution. The 
chromagen formed from MDA-TBA adduct is quantified spectrophotometrically 
(Ohkawa et al., 1978) or fluorometrically (Janero, 1990). 
2.1.4 CLA and Atherogenesis 
CLA supplementation could significantly lower the risk of atherosclerotic 
development in rabbits (Lee et al., 1994) and hamsters (Nicolosi et al., 1997), but the 
observation from these in vivo studies was mainly related to the hypolipidemic effect 
of CLA. More recently, a contradictory finding from Munday et al. (1999) showed 
that CLA might promote fatty streak formation in mice though it had serum lipid 
lowering effect. As a result, no absolute conclusion can be drawn from these 
contradictory observations. 
27 
2.2 Objective of the Present Study 
The antioxidant effect of CLA on LDL oxidation has not been studied 
previously. Therefore, the objective of the present study was to investigate the 
effect of CLA on human LDL oxidation in vitro. In this study, Cu^^-mediated 
oxidation system was employed and the measurement of TBARS formation was used 
as an oxidation index. 
/ 
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2.3 Materials and Methods 
2.3.1 Human LDL Isolation 
Fresh human blood samples were collected from healthy subjects at the Prince 
ofWales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong. The 
LDL was isolated using the method of Havel et al. (1955), with a few modifications. 
In brief, appropriate volume of an aqueous solution containing 10 % EDTA (from 
Sigma) and 0.5 % NaN3 was added to freshly prepared plasma to obtain a final 
plasma concentration of 0.1 % EDTA and 0.05 % NaN3. EDTA served as metal 
chelator and NaN3 served as anti-bacterial agent to prevent lipoprotein modification. 
In order to minimize the oxidation of LDL, the centrifuge tube containing plasma 
was flushed with nitrogen gas. The plasma was then centrifuged at 10�C and 1000 
g for 10 minutes to remove cells and all cellular debris. 
I 
The density of plasma was adjusted with NaCl-KBr solution, containing 15.3 % 
NaCl and 35.4 % KBr with 100 mg EDTA, to a density of 1.019 g / ml. The density 
solution was purged with nitrogen before use. The plasma was then re-centrifuged 
at 10�C and 16,000 g for 20 hours. After centrifugation, the top layer containing 
very low-density lipoprotein (VLDL) and chylomicron was removed. 
The remaining bottom plasma fraction was then adjusted with NaCl-KBr 
solution to a density of 1.063 g / ml and re-centrifoged at 10�C and 16,000 g for 24 
hours. The top LDL fraction, characterized by the yellow color due to endogenous 
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3-carotene, was collected and the protein content of the isolated LDL was 
determined by Lowry's method (Lowry et al., 1951). For storage, the LDL stock 
solution was sterile-filtered through a 0.2 -|um filter adapted to a syringe and stored 
in —70�C with nitrogen purge. 
2.3.2 LDL Oxidation 
Before usage, the stock LDL solution (5 mg protein / ml) was dialyzed against 
100 volume of dialysis solution, containing 0.01 M sodium phosphate pH 7.4, 0.9 % 
NaCl, 0.01 % EDTA and 0.05 % NaN3, in dark for 24 hours. The dialysis solution 
was changed four times, and dialysis was performed under nearly anoxic condition in 
nitrogen filled stoppered bottle at 4°C. 
Oxidation ofLDL was conducted as previously described by Puhl et al. (1994). 
In this method, 100 ^g LDL protein was incubated with 5 i^M CuS04 and 0.75-10 
i^M bovine serum albumin (BSA), or 2.5-20 mM LA (from Sigma) in 1.5 i^M BSA, 
or 2.5-20 mM CLA (from Natural Lipids Ltd., Norway) in 1.5 ^M BSA at 37�C for 
up to 24 hours. The oxidation was stopped by addition of 25 ^1 1 % EDTA solution 
and the mixture was cooled at 4°C. 
2.3.3 Thiobarbituric Acid Reactive Substances (TBARS) Assay 
The extent of LDL oxidation was monitored by measuring the formation of 
TBARS (Buege & Aust, 1978; Janero, 1990). Two ml TBA-TCA-HC1 solution, 
containing 0.67 % thiobarbituric acid, 15% trichloroacetic acid and 0.1 N HC1, was 
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added to reaction mixture. The reaction mixture was then heated at 95°C for 60 
minutes. After cooled down on ice and centrifuged at 1000 g for 10 minutes, the 
supernatant containing TBARS was determined spectrophotometrically at 532 nm. 
Calibration was done with a malonaldehyde (MDA) standard prepared from 
tetramethoxypropane. The value was expressed as nmol of MDA formed per mg 
LDL protein. 
2.4 Statistics 
Results are expressed as mean 士 standard deviation (SD). One-way analysis of 
variance (ANOVA) and Student's ,-test were used where applicable for statistical 





2.5.1 Inhibitory Effect of BSA on Human LDL Oxidation 
Effects of BSA on human LDL oxidation initiated by 5 juM CuSO4 were 
examined, and the degree of oxidation was monitored by measuring the formation of 
TBARS. As shown in Figure 2.4, LDL was significantly oxidized within 4 hours in 
the absence of BSA. The formation of TBARS peaked at 8-hour incubation. 
Protective effect of BSA on LDL oxidation was demonstrated in a dose-dependent 
manner, ranging from 0.75 ^M to 10 ^M (p<0.01). Addition of 3 i^M BSA could 
significantly delay the propagation of LDL oxidation and extend the lag-time more 
than 12 hours. In the presence of 4.5 ^M, 6 ^M and 10 \jM ofBSA, LDL oxidation 
was not detectable throughout the period of 24-hour incubation. 
2.5.2 Pro-oxidant Effect ofLA on Human LDL Oxidation 
As compared with the incubation with 1.5 |uM BSA only, addition of LA 
showed a pro-oxidant effect on LDL oxidation (Figure 2.5). The pro-oxidant effect 
ofLA was also dose-dependent (2.5 mM to 20 mM). 
2.5.3 Inhibitory Effect of CLA on Human LDL Oxidation 
CLA in BSA was protective on LDL oxidation. As shown in Figure 2.6, CLA 
protected LDL against oxidation in a dose-dependent manner, ranging from 2.5 mM 
to 20 mM of CLA. When 2.5 mM and 5 mM of CLA were added, the LDL 
oxidation was delayed up to 12 hours. Moreover, oxidation ofLDL was almost 
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Figure 2.4 Inhibitory effect of bovine serum albumin (BSA) on the production of 
thiobarbituric acid reactive substances (TBARS) in Cu^^-mediated oxidation ofhuman 
LDL. Data are expressed as mean 土 SD of n=3-4. Means at the same ^ime point 
with different letters (a-d) differ significantly (p<0.01). -
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Figure 2.5 Stimulatory effect of linoleic acid (LA) on the production of 
thiobarbituric acid reactive substances (TBARS) in Cu^^-mediated oxidation ofhuman 
LDL. Data are expressed as mean 土 SD of n=4. Means at the same time point with 
different letters (a-e) differ significantly Q)<0.01). 
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Figure 2.6 Inhibitory effect of conjugated linoleic acid (CLA) on the production of 
thiobarbituric acid reactive substances (TBARS) in Cu^^-mediated oxidation ofhuman 
LDL. Data are expressed as mean 土 SD of n=4. Means at the same time point with 
different letters (a-d) differ significantly (p<O.Ol). — 
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undetectable throughout the 24-hour incubation period, in the presence of 5 mM to 
20 mM ofCLA. 
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2.6 Discussion 
2.6.1 Effect of BSA on Copper-Induced LDL Oxidation 
The present study showed that addition ofBSA could protect LDL against Cu�+-
induced oxidation. Moreover, the protective effect of BSA was dose-dependent 
(0.75 pM to 10 fiM). This is in agreement of the findings by Thomas (1992) and 
Deigner et al. (1992). They proposed that albumin was ideally suited as a plasma 
antioxidant to prevent oxidation modification of LDL induced by copper ion, and it 
might reduce modification of LDL, resulting in reduce of atherogenicity. The major 
mechanism responsible for the protective effect of albumin against copper-induced 
oxidation is due to the binding of copper to albumin. Copper ions can bind to the 
binding sites on albumin in several orders of magnitude tighter than to LDL. Also, 
the rate of production of free radicals from the Cu^7BSA complex is much slower 
than the rate of production of free radicals during oxidation promoted by free copper 
ions (Schnitzer et al., 1997). From the present study, addition of 4.5 i^M or higher 
concentration of BSA showed a complete inhibition of LDL oxidation. This can be 
explained by the findings from Schnitzer et al. (1997). In their study, when the 
Cu'7BSA molar ratio lower than 1 (e.g., 4.5 i^M BSA at 4 i^M Cu"+ or 10.5 ^M BSA 
at 9 i^M Cu2+), all the copper ions were expected to be bound tightly to the binding 
sites in BSA, and this would alter the kinetic of LDL oxidation. As a result, LDL 
oxidation would be diminished. 
Since LA and CLA both are hydrophobic molecules, they are hardly soluble in a 
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relatively hydrophilic assay buffer system. Therefore, BSA was added into the 
present assay system, in order to increase the miscibility of LA and CLA in the 
incubation mixture. It was found that mixing 1.5 ^M BSA with LA and CLA wasO 
the most effective. Furthermore, through studying the influence of BSA on LDL 
oxidation, the effect of 1.5 i^M BSA on LDL-oxidation was relatively small. Thus, 
1.5 i^M BSA was chosen to mix LA or CLA. 
2.6.2 Effect of LA on Copper-Induced LDL Oxidation 
The present study demonstrated that LA was a pro-oxidant. LA was unable to 
act as antioxidant and scavenge free radicals because it might be oxidized by Cu�+ 
similar to other PUFAs. Once LA was oxidized, the formation of conjugate diene 
and lipid peroxy radicals, P_fragmentation and occurrence of aldehydes would take 
place (Porter et al., 1995). Thus, a high level of TBARS formation was expected. 
Maziere et al. (1998) proposed that n-3 and n-6 PUFAs with a high degree of 
unsaturation could accelerate LDL peroxidation and, thus, aggravate the 
atherosclerotic process. As n-6 PUFAs are the most abundant fatty acids in human 
LDL (Jira et al., 1998), LA is thought to be atherogenic. In fact, the Kuopio 
Atherosclerosis Prevention Study (KAPS) has shown that an increase in dietary LA 
was associated positively with the oxidation susceptibility of VLDL and LDL in men 
(Louheranta et al., 1996). Moreover, increased intake ofLA significantly increased 
the risk for CHD (Blankenhom et al., 1990). 
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However, a different profile of inhibitory effect by 1.5 jaM BSA was observed 
in this experiment. This was probably due to that 1.5 |iM BSA might be a 
borderline concentration on the protection of LDL against oxidation. As mentioned, 
the protective effect of BSA is dependent on the Cu^7BSA ratio, but it is easily 
affected by different experimental conditions. Therefore, the minor experimental 
differences in the present study might lead to this different observation. 
2.6.3 Protective Effect of CLA on Copper-Induced Human LDL Oxidation 
The present study showed that CLA acted as an effective antioxidant and 
significantly protected human LDL against copper-induced oxidation in a dose-
dependent manner in addition to its hypolipidemic activity. However, our previous 
study found that CLA was a pro-oxidant and oxidized much faster than LA in air 
(Chen et al., 1997). Perhaps, CLA may function as both antioxidant and pro-
oxidant dependent on the test conditions. 
Under the present conditions, CLA acted as an effective antioxidant. In this 
regards, CLA may function as an antioxidant by the mechanism proposed by Ha et al. 
(1990). In their study, CLA was found as a more potent antioxidant than a-
tocopherol and almost as effective as butylated hydroxytoluene (BHT). The 
proposed mechanism involves the transformation of the conjugated diene to a p_ 
hydroxy acrolein moiety. The antioxidant activity may result from resonance 
enolization of the p-hydroxy acrolein moiety; and/or the p-hydroxy acrolein moiety 
may chelate Cu�+ to interfere Fenton reaction (Figure 2.7). In other words, an 
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Figure 2.7 A proposed model for the conversion of CLA to an active antioxidant. 
The sequence involves reaction of either carbon bordering the conjugated diene 
system with hydroxyl or peroxyl radical, followed by reaction of the distant double 
bond with molecular oxygen, to produce a p-hydroxy acrolein moiety. Antioxidant 
activity most likely results from the chelation of Cu�+ by the p-hydroxy acrolein 
moiety (thereby interfering with the Fenton reaction) and perhaps also from resonance 
enolization (adapted from Ha et al., 1990). 
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oxidized derivative of CLA may act as antioxidant instead. Moreover, CLA 
molecule may facilitate the binding of copper ion to BSA molecule. As mentioned, 
BSA can delay LDL oxidation by the formation of Cu^VBSA complex. Therefore, 
if CLA can increase the affinity of BSA to Cu�+, it can certainly inhibit oxidative 
modification of LDL through indirect mechanism under the present experimental 
conditions. 
It remains unclear whether dietary CLA can exert antioxidant effect in vivo. It 
is possible that increase in dietary CLA may increase the incorporation of CLA into 
the lipids of LDL. CLA, as lipophilic molecule, may scavenge lipophilic radicals 
within LDL to break the free radical chain propagation. In this way, LDL is 
protected from oxidative modification not only by native endogenous antioxidants 
(a-tocopherol, y-tocopherol and p-carotene), but also by CLA. 
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Chapter 3 
Hypolipidemic Activity of CLA 
3.1 Introduction 
3.1.1 Total Cholesterol and LDL Cholesterol 
According to a survey from World Health Organization (WHO), coronary heart 
disease (CHD) is the leading cause of death in many developed countries (Figure 
3.1). High serum cholesterol is a most risk factor in the development of CHD. 
It was discovered 80 years ago that feeding cholesterol to rabbits would cause 
atherosclerosis (Grundy & Denke, 1990). The relationship between high serum 
cholesterol, especially the LDL cholesterol, and risk of CHD has been studied 
intensively. More and more investigations have demonstrated that high serum total 
cholesterol is positively related to the risk of CHD. It has been demonstrated that 
high serum cholesterol is a single, independent factor associated with CHD (Rifkind 
& Lenfant, 1986). The epidemiological data also reinforce this hypothesis. For 
instance, from the Framingham study and the Oslo study, high serum cholesterol 
(210 to 220 mg / dL) was positively associated with the mortality of CHD in 
univariate and in multivariate analyses (Anderson et al., 1987; Holm et al., 1985). 
Moreover, from the Multiple risk factor Invention Trial study, over 350,000 men 
from different races were screened for the relationship between serum cholesterol 
and CHD. It was found that semm cholesterol with the concentration about 170 mg 
/ dL would positively link to the risk of CHD (Neaton et aL, 1984). 
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Figure 3.1 Standardized mortality rates in men (1986-1988), World Health 
Organization, (adapted from Newton, 1996) 
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On the other hand, HDL-cholesterol is always thought as "good" cholesterol. 
From epidemiological studies, the level of HDL cholesterol was found to be 
inversely related to the risk of CHD in human (Miller & Miller, 1975; Holme et al., 
1985). HDL can deliver its cholesterol to liver and other steroid-synthesizing cells 
through the scavenger receptor BI (SR-BI). SR-BI is a HDL receptor which can 
tightly bind to HDL and enable cells to capture cholesterol from HDL particles 
(Huster, 1997). HDL may also play a critical role in atherogenesis. HDL could 
protect LDL against metal-ion induced oxidation by increasing the HDL associated 
paraoxonase and lecithin:acetyl cholesterol acyltransferase activity. Moreover, 
HDL inhibits the oxidized LDL-induced hyperadhesiveness of monocytes to 
endothelial cells (Holvoet & Collen, 1999). Furthermore, the ratio of TC to HDL-
cholesterol was a critical determinant of atherogenesis, and it could be considered as 
an important index of the risk for CHD (Gordon et aL, 1977). When the ratio was 
high, the risk for CHD was increased and vice versa (Abbott et al., 1988). 
3.1.2 Triglyceride (TG) 
Less attention has been given to the serum TG level than to the semm 
cholesterol level. It is still an open issue that a high level of serum TG is an 
independent risk factor for CHD (Hulley et al., 1980). The widely held view is that 
elevated TG level is not an important risk factor for CHD (Wilhelmsen et al., 1973). 
A number of investigations have shown that serum TG was not associated with the 
risk of CHD independently (Holme et al., 1985; Pocock et al., 1989). For example, 
in the Honolulu study and the Oslo study, TG did not appear to be significantly 
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associated with CHD in a multivariate analysis (Rhoads et al., 1978; Holme et al., 
1985). 
However, some recent epidemiological data revealed a significant positive 
correlation between serum TG and CHD risk. Thus, serum TG may be an 
independent risk factor for CHD (Carlson et al,, 1972 & 1979; Gotto et al., 1977; 
Carlson & B6ttiger, 1985; Lapidus et al., 1985, Cambien et al., 1986). For instance, 
the Frammingham study proposed that higher serum TG concentrations were linked 
to increased risk of CHD, if the ratio of total cholesterol to HDL cholesterol 
concentration was over 3.5 (Castelli, 1986; Fox et al., 1987). Also, from the 
Stockholm Ischaemic Heart Disease Secondary Prevention Study, it was found that 
patients having 30% or more reduction of serum TG level showed 60% reduction of 
CHD mortality (Carlson & Rosenhamer, 1988). Moreover, high serum TG appears 
to be underlying cause of several putative lipid risk factors for CHD, for instance, 
reduced levels of HDL cholesterol and raised levels of chylomicron remnants, VLDL 
remnants, IDL and LDL (Richards et al,, 1989; Grundy & Vega, 1988). 
3.1.3 Hypolipidemic Effect of CLA 
Sine 1970, a series of studies were taken to examine the relationship between 
reduced semm cholesterol and the risk of CHD. It is found that lowering 
cholesterol can reduce the risk of CHD, though that is not a linear relationship (Fazio 
& Linton, 1998). Moreover, a large variety of hypolipidemic agents, including bile 
acids, phytosterol and HMG-CoA reductase inhibitors, are tested for their efficacy in 
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reducing CHD mortality 
CLA, as a naturally occurring fatty acid present in foods, is also found to exhibit 
novel hypolipidemic effect. Consumption of CLA (0.5 g / per day) could 
effectively lower the plasma TC and TG in rabbits fed a high-fat diet (Lee et al., 
1994). Also, dietary CLA (0.06 en %, 0.11 en % and 1.1 en %) significantly 
reduced levels of plasma TC, non-HDL cholesterol and TG in hamsters fed a high-
cholesterol diet (Nicolosi et al,, 1997). However, the mechanism involved is still 
unknown. More recently, it was found that dietary CLA could significantly reduce 
serum TG level, non-esterified fatty acids in liver and white adipose tissue (WAT), 
but those in the brown adipose tissue (BAT) were unchanged in Sprague-Dawlet rats 
(Yamasaki etal., 1999). 
3.1.4 Golden Syrian Hamster as an Animal Model of Cholesterol 
Metabolism 
Golden syrian hamster {Mesocricetus Auratus) is a common rodent widely used 
as an experimental animal model in studying of cholesterol metabolism (Singhal et 
al., 1983), atherosclerosis (Nistor et al., 1987) and hypocholesterolemic agents 
(Sugiyama et al,, 1995). Similar to human, its major plasma cholesterol carrier is 
LDL. By using electrophoresis in agarose gel, it is found that about 50 % of 
hamster's plasma cholesterol occurs in the LDL fraction. Moreover, hamster LDL 
cross-reacts with antibody raised against human LDL (Nistor et al., 1987). Other 
similarities include similar response to different diets and drugs, and manner in 
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handling biliary sterol secretion (Bocan & Guyton, 1985; Spady & Dietschy, 1984). 
The advantage in choosing hamsters is also partially due to their low rate of 
hepatic cholesterol synthesis. It is because increased hepatic influx of absorbed 
cholesterol could not be compensated in the species by down-regulation of 
cholesterol synthesis, but may alter hepatic cholesterol excretion (Berr et al., 1993). 
In this way, the factor from hepatic cholesterol synthesis can be negligible. 
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3.2 Objectives of The Present Study 
Several previous studies have demonstrated that dietary CLA supplementation 
can reduce the serum cholesterol and TG as well as the risk of atherosclerosis in 
different animal models including rabbits and hamsters (Lee et al., 1994; Nicolosi et 
al., 1997). However, there is still limited information to date addressing the 
mechanisms for the hypolipidemic activity of dietary CLA. Therefore, the objectives 
of the present study were to study the hypolipidemic effect of dietary CLA in 
hamsters and examine the possible mechanisms whereby CLA exerts its 
hypolipidemic effect. 
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3.3 Materials and Methods 
3.3.1 LA and CLA 
LA, cis-9, cis-12-octadecadienoic acid, used in this experiment was purchased 
from Sigma Chemical Co. with purity over 98.5 %. CLA (Tonalin™ CLA 90%) of 
high grade purity was a generous gift from Natural Lipids ltd. AS, Norway. The 
purity of CLA was over 82 % and the fatty acid composition was shown in Table 3.1. 
3.3.2 Animals 
Male Golden Syrian hamsters were housed in polystyrene cage (2-3 hamsters 
per cage) in a room of 23°C with alternating cycles of 12-h light (7:00am to 7:00pm) 
and 12-h darkness. All hamsters were habituated for 1 week before experiment. 
Fresh semi-synthetic diets were given to hamsters daily, and the uneaten food was 
discarded. Daily consumption of diet and body weight were recorded and the fecal 
output from each cage of hamsters was collected. The hamsters were allowed to 
access food and water ad libitum. 
3.3.3 Experiment 1 
Thirty-six hamsters (125-140 g) were fed a commercial non-purified ration 
during the first week acclimation period. The animals were then divided randomly 
into three groups (n=12 per group) with approximately equal mean group body 
weights, and maintained on one of three different experiment diets for eight weeks. 
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Table 3.1 Composition of conjugated linoleic acid (CLA) used in the present 
experiment. 
Fatty acid profile, GC Common name % of total fatty acids 
16:0 Palmitic acid L79±0.11 
18:0 Stearic acid 0.66±0.03 
18:1 c9 Oleic acid 5.68±0.26 
18:2 c9,cl2 Linoleic acid 0.59±0.02 
18:2, conjugated total CLA 82.49 士 0.27 
18:2, conjugated c9, tll CLA-isomer 32.76 士 0.04 
18:2’ conjugated tlO, cl2 CLA-isomer 33.80 ± 1.58 
18:2, conjugated c9, cll CLA-isomer L24±0.16 
18:2, conjugatedclO, cl2 CLA-isomer 14.68 ± 1.11 
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The experimental diets were comprised of a semi-synthetic and high-cholesterol diet, 
with supplementation of 2% L A or 2 % CLA. The semi-synthetic diets were 
prepared with the method described by Sanders & Sandaradura (1992) with little 
modifications (Table 3.2). The fatty acid composition of the semi-synthetic diet 
was determined by gas-liquid chromatography (GLC) (Table 3.3). The powder diet 
was then mixed with gelatin solution (20 g /L). Once the gelatin had set, the diet 
was cut into ~20 g cubed portions, and stored frozen at — 20。C. 
At the end of 8 weeks, all hamsters were killed after ovemight fasting and blood 
was collected via the abdominal aorta under nitrogen anesthesia. After clotting, the 
blood was centrifuged at 1500 g for 10 min., and the serum was then collected. 
Liver and perirenal adipose tissue (1 pad) were removed, washed with saline and 
weighed after exsanguination. All the organ samples were then stored at —76°C 
before lipid analysis. 
3.3.4 Experiment 2 
The objective of experiment 2 was to examine the effect of dietary C L A on the 
hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and 
intestinal acyl conenzyme A: cholesterol acyl transferase (ACAT). Thirty hamsters 
(125-140 g), were divided randomly into three groups (n=10). The feeding 
conditions were the same as those in experiment 1 except that, at the end of 8 weeks, 
all hamsters were sacrificed without ovemight fasting (full stomach). This is 
because the intestinal A C A T is inducible by dietary cholesterol. The activity of 
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Table 3.2 Composition of experimental diets 
Content (% w/w) Control L A C L A 
C o m starch 48.8 47.8 47.8 
Casein 20.0 20.0 20.0 
Lard 10.0 10.0 10.0 
Sucrose 15.0 14.0 14.0 
Mineral Mix 4.0 4.0 4.0 
Vitamin Mix (ArN-76) 2.0 2.0 2.0 
DL-Methionine 0.1 0.1 0.1 
Cholesterol 0.1 0.1 0.1 
Linoleic acid (LA) / 2.0 / 
Conjugated linoleic acid (CLA) / / 2.0 
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Table 3.3 Fatty acid composition of the semi-synthetic diet*. 
Fatty acid Common name % of total fatty acids 
14:0 Myristic acid 2.14 士 0.02 
16:0 Palmitic acid 27.59±0.14 
16:ln-7 Palmitoleic acid 1.99±0.00 
18:0 Stearic acid 16.32±0.08 
18:ln-9 Oleic acid 33.14±0.16 
18:2n-6 Linoleic acid 10.21 士 0.07 
18:3n-3 Linolenic acid 0.19±0.01 
20:4n-6 Arachidonic acid 0.06 士 0.00 
20:5n-3 Eicosapentanoic acid 0.28 ±0.04 
* The supplemented linoleic acid (LA) and conjugated linoleic acid (CLA) were not 
included. 
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intestinal A C A T was maintained at a high level when the hamsters were not fasted. 
Blood was collected through the abdominal aorta under nitrogen anesthesia. Liver, 
heart, kidney, brain, muscle (from adductor longus), epididymal and perirenal 
adipose tissues, and intestine were removed, washed with saline, and weighed after 
exsanguination. All the organ samples were then freeze-clamped and stored at -
76。C before analysis. 
3.3.5 Determination of Serum TC, HDL-Cholesterol (HDL-C) and T G 
Semm was collected after blood clotting and centrifugation at 1,300 g for 10 
min. Serum T G and TC levels were determined by using enzymatic kits (Sigma 
Chemical Co., St. Louis, M O , USA). HDL-C was measured after the precipitating 
LDL and V L D L with phosphotungstic acid and magnesium chloride with a 
commercial kit (Sigma). 
3.3.6 Lipid Analysis of Liver and Adipose Tissue 
3.3.6.1 Lipid Extraction and Separation of Different Lipid Species 
The lipids from liver (300 mg) and adipose tissue (100 mg) were extracted. 
Triheptadecanoic acid (Sigma) and L- 6^ -phosphotidylcholine diheptadecanoyl 
(Sigma) were added as internal standards for quantifying the contents of T G and 
phospholipid (PL), respectively. Chloroform-methanol (2:1, v/ v) and saline were 
added for extraction, and the mixture was homogenized using a Polytron 
homogenizer. The chloroform-methanol phase was collected and dried under a 
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gentle stream of nitrogen gas. The lipid extract was then re-dissolved in chloroform. 
An aliquot of lipid extract was applied to a thin-layer chromatography (TLC) plate 
(20 X 20 cm, pre-coated with 250 ^im silica gel 60A; Macherey-Nagel, Duran, 
Germany) to separate different lipid classes. A solvent system of hexane: diethyl 
ether: acetic acid (80:20:1, v/ v/ v) was used for TLC development. The bands 
containing T G and PL were scraped off from the plate. 
3.3.6.2 Acid-Catalyzed Methylation of Fatty Acids 
The lipid extracts, T G and PL fractions were converted to corresponding methyl 
esters using acid-catalyzed methylation method (Luddy et al., 1960). The reason 
using acid-catalyzed methylation method was because other methylation methods, 
like boron trifluoride ( B F 3 ) methylation, would lead to a large-scale chemical 
conversion of C L A isomers (Chin et al., 1992). The lipid samples were dissolved 
in tetrahydrofuran and 2 ml of 5% methanolic hydrogen chloride was added. The 
mixture was then incubated at 60。C for ovemight. The fatty acid methyl esters 
(FAME) were extracted with hexane. After centrifugation, the hexane layer was 
collected and then subjected to G L C analysis. 
3.3.6.3 G L C Analysis of F A M E 
The F A M E were analyzed on a flexible silica capillary column (SP 2560, 100 m 
X 0.25 mm, i.D.; Supelco, Inc., Bellefonte, PA) in an HP 5980 Series II gas-liquid 
chromatograph, equipped with a flame-ionization detector (Hewlett-Packard). 
Column temperature was programmed from 180 to 220。C at a rate of rC/min and 
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then held for 20 min. Hydrogen was used as the carrier gas at a head pressure of 20 
psi. 
3.3.7 Quantification of tissue cholesterol 
3.3.7.1 Cholesterol extraction and its silylation 
Three hundred milligrams of different tissues were weighed and stigmastanol 
(from Sigma) was added as an internal standard. The samples were then 
homogenized in 15 ml chloroform-methanol (2:1, v/ v) and 3 ml saline using a 
Polytron homogenizer. After centrifugation, the bottom chloroform-methanol phase 
was collected and dried under a gentle nitrogen stream. The samples were 
subjected to alkaline hydrolysis with 5 ml of lN N a O H in 90% ethanol at 90。C for 1 
hour. One milliliter of distilled water and 6 ml of cyclohexane were added for 
cholesterol extraction. The upper cyclohexane phase was collected and evaporated 
under nitrogen. Cholesterol in the samples was then converted to its trimethylsilyl 
(TMS)-ether derivative by using a commercial TMS-reagent (dry pyridine-
hexamethyldisilazane-trichlorosilane, 9:3:1, v/ v/v, Sil-A regent, Sigma). After 
incubated at 60。C for 1 hour, the mixture was dried under nitrogen. The TMS-ether 
derivative was dissolved in 600 fil of hexane, and after centrifugation, the hexane 
phase was transferred to a vial for GLC analysis. 
3.3.7.2 GLC Analysis of TMS-Ether Derivative of Cholesterol 
The TMS-ether derivative was analyzed on a fused silica capillary column 
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(SAC™-5, 30 m x 0.25 mm, i.d.; Supelco, Inc., Bellefonte, PA) in a Shimadzu GC-
14B gas-liquid chromatograph equipped with a flame-ionization detector (Shimadzu). 
Column temperature was programmed at 285。C and maintained for 20 min. Helium 
was used as the carrier gas at a head pressure of 22psi. A typical G L C 
chromatogram of tissue cholesterol was shown in Figure 3.2. 
3.4 Statistics 
Data were expressed as mean 士 standard deviation (SD). The group means 
were statistically analyzed using one-way analysis of variance (ANOVA) and 
Student's 广-test on SigmaStat Advisory Statistical Software (SigmaStat version 2.01, 
SPSS Inc., Chicago, IL, USA). The difference was considered significant when p 
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Figure 3.2 Gas-liquid chromatographic profile of hepatic cholesterol and internal 
standard (stigmastanol). See text for the conditions of separation. 
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3.5 Results 
3.5.1 Body Weight and Food Intake 
There was no significant difference in food intake and body weight gain among 
the three groups throughout the study period (Table 3.4), although hamsters in CLA-
supplemented group showed lesser body weight gain and food intake as compared 
with the CTL and L A groups. However, C L A supplementation altered individual 
organ weight in experiment 2 in which the average liver and kidney weight increased, 
and the adipose tissue weight decreased (Table 3.5). 
3.5.2 Effect ofDietary CLA Supplementation on Serum TG, TC 
and HDL-C 
Fasting serum TG was markedly decreased by 35 % and 25 % (p<0.01) in 
hamsters fed with 2 % CLA-supplemented and 2 % LA-supplemented diets in 
experiment 1 (Figure 3.3). However, there was no significant difference in serum 
TG among the control, LA-supplemented and CLA-supplemented groups in 
experiment 2, where the hamsters were sacrificed without ovemight fasting. 
Similarly, dietary CLA and LA supplementation significantly reduced the 
fasting serum TC by 12 % and 13 % (p<0.01), respectively, in experiment 1 only 
(Figure 3.4). In experiment 2, there was no difference in non-fasting serum TC 
among the three groups, although the CLA-supplemented group had a slightly lower 
level ofTC. 
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Table 3.4 Effect of 2 % L A and 2 % C L A supplementation on body weight and 
food intake in hamsters 
Experiment 1 
control (12)^  2 % L A (12) 2 % C L A (12) 
Initial body weight (g) 120.83 士 7.93 121.25 士 8.01 120.83 士 7.64 
Final body weight (g) 166.67 士 10.52 167.5 士 16.72 161.25 土 12.27 
Food intake (g / day) 13.96±2.37 13.96±2.38 13.87±2.63 
Experiment 2 
control (10) 2%LA(10) 2%CLA(10) 
Initial body weight (g) 116.50±7.37 117.90± 8.28 116.70±6.06 
Final body weight (g) 148.96 土 11.96 152.24 士 14.27 142.74 土 10.98 
I 
Food intake (g / day) 9.96±1.23 10.11±1.01 9.57i0.78 ！ 
I 
1 Figures in parentheses indicate the number ofhamsters used. 
Data are expressed as means 士 SD. 
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Table 3.5 Individual organ weights from hamsters in experiment 2 
Organ (weight in g) control (10) ^  2 % L A (10) 2 % C L A (10) 
Liver 7.57±0 . 82b 8.05±0.63" 8.8211.07& 
Epididymal adipose tissue 1.70 土 0.20& 1.90 士 0.23' 1.45 士 0.29' 
Peri-renal adipose tissue 1.27 土 0.23' 1.47 土 0.24& 1.05 士 0.29' 
Kidney 0.52 士 0.05。 0.54 士 0.04' 0.56 士 0.05& 
Heart 0.48 士 0.04 0.48 士 0.04 0.48 土 0.04 
Brain 0.97±0.10 0.98 ±0.05 0.96±0.08 
1 Figures in parentheses indicate the number ofhamsters used. 
Data are expressed as means 士 SD. 
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Figure 3.3 Effects of dietary 2% L A and 2 % C L A supplementation for 8 weeks on 
serum triglyceride (TG) level. The hamsters in experiment 1 were killed after 
ovemight fasting while the animals in experiment 2 were sacrificed without ovemight 
fasting. Data are expressed as means 土 SD of n=12 (experiment 1) and n=10 
(Experiment 2). Significant differences are indicated by ** p<0.01. 
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Figure 3.4 Effects of dietary 2% L A and 2% C L A supplementation for 8 weeks on j 
serum total cholesterol (TC) level The hamsters in experiment 1 were killed after I 
ovemight fasting while the animals in experiment 2 were sacrificed without overnight j 
fasting.. Data are expressed as means 土 SD of n=12 (Experiment 1) and n=10 
(Experiment 2). Significant differences are indicated by ** p<0.01. 
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Neither dietary 2 % C L A nor 2 % L A supplementation had significant effect on 
the semm HDL-C level in both experiment 1 and experiment 2 (Figure 3.5). On the 
other hand, dietary C L A and L A supplementation reduced (p<0.05) the ratio ofTC to 
HDL-C in experiment 1 only (p<0.05) (Figure 3.6). 
3.5.3 Effect of Dietary CLA Supplementation on Hepatic TG, Phospholipid 
and Cholesterol 
All three groups had similar level of fasting hepatic T G in experiment 1, but the 
non-fasting hepatic T G levels were raised by 29 % and 30 % (p<0.05) in the LA- and 
CLA-supplemented groups as compared with that of the control group in experiment 
2 (Figure 3.7). The fatty acid composition of hepatic T G was also changed by 
different experimental diets (Table 3.6 & 3.7). Different C L A isomers were 
incorporated into hepatic T G fraction (2.03% of total liver TG) in the CLA-
supplemented group. Also, a trace amount of cis-9, trans-11 C L A isomer was 
I 
found in both control and LA-supplemented groups (<0.16% of the total liver TG). : 
Moreover, LA (18:2n-6) and the metabolites of LA (20:3n-6, 20:4n-6 and 22:4n-6) 
were found to be higher in LA-supplemented group than the other two groups. 
Hepatic PL was markedly increased in CLA-supplemented group (p<0.01), and C L A 
isomers were found to be incorporated into PL fraction (Table 3.8 & 3.9). 
As compared with the unsupplemented control, hepatic cholesterol was 
significantly (p<0.01) lowered by 65 % (experiment 1) and 26 % (experiment 2) in 
CLA-supplemented group (Figure 3.8). 
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I： Figure 3.5 Effects of dietary 2% L A and 2 % C L A supplementation for 8 weeks on ； 
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serum HDL-cholesterol (HDL-C). The hamsters in experiment 1 were killed after !: 
ovemight fasting while the animals in experiment 2 were sacrificed without ovemight 
fasting. Data are expressed as means 土 SD of n=12 (Experiment 1) and n=10 
(Experiment 2). 
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I： i Figure 3.6 The ratio of serum total cholesterol to HDL-cholesterol among the ； 
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control, LA-supplemented and CLA-supplemented groups. The hamsters in I: 
experiment 1 were killed after ovemight fasting while the animals in experiment 2 
were sacrificed without ovemight fasting. Data were expressed as means 土 SD. 
The significant difference is indicated as * p<0.05. 
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Figure 3.7 Hepatic triglycerides (TG) (mg / g) among the control, LA-
supplemented and CLA-supplemented groups. The hamsters in experiment 1 were 
killed after ovemight fasting while the animals in experiment 2 were sacrificed 
without ovemight fasting. Data are expressed as means 土 SD of n=12 (Experiment 1) 
and n-=10 (Experiment 2). The significant difference is indicated as * p<0.05. 
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Table 3.6 Effect of dietary C L A supplementation on the composition of hepatic 
triglyceride (TG) (Experiment 1) 
FatIy Acids CTL 2% LA 2 % C L A ~ 
Saturated fatty acids 
16:0 23.57 (1.90) 22.07 (1.72) 21.71 (4.49) 
18:0 4.13(0.55)b 4.25(0.56)b 5.71(1.13^ 
MUFA 
16:1n-7 2.52(1.36) 2.46 (0.63) 1.37 (0.79) 
18:1 n-9 52.54 (3.07f 44.54 (2.65)' 51.18 (3.25)^  
18:1n-7 2.64(1.32) 2.89 (0.32) 2.67(1.03) 
20:1n-7 0.40(0.26)b 0.51 (0.18f 0.14(0.28)。 
n-6 PUFA 
18:2n-6 11.37(1.14)b 19.55 (1.65f 9_17(1_38)。 
20:2 n-6 0.00 (O.OOf 0.02 (0.05)" 0.00 (O.OOf 
20:3 n-6 0.00 (0.00)' 0.01 {0.04f 0.00 (O.OOf 
CLA 
c-9. M1/f-9, c-11-18:2n 0.00 (O.OOf 0.00 (O.OOf 0.91 (0.65f 
c-10, M2/M0,c-12-18:2n 0(0广 0(0广 0.13(0.42)" 
l^al TG weight (mg / g) 2.89(1.17) 2.83(1.11) 2.78(0.93)  
Data are expressed as wt. % of total TG. 
Means at the same row with different superscripts (a’b’c) differ significantly Q)<0.01) 
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Table 3.7 Effect of dietary C L A supplementation on the composition of hepatic 
triglyceride (TG) (Experiment 2). 
Fatty Acids CTL 2 % LA 2 % C L A ~ 
Saturated fatty acids 
12:0 13.54 (3.74) 10.55 (2.41) 11.98 (3.81) 
14:0 0.23(0.02) 0.23(0.05) 0.24 (0.03) 
15:0 0.11 (0.02) 0.14(0.16) 0.11 (0.02) 
16:0 20.17 (1.56)b 20.90 (1.79f 24.47 (1.56)^ 
18:0 4.42(0.52)b 4.36 (0.37f 5.82 (0.57f 
M U F A 
16:1 n-9 0 . 7 3 (0.31) 0.83 (0.19) 0.71 (0.12) 
16:1n-7 1 . 9 2 ( 0 . 2 1 ) 2 . 0 8 ( 0 . 3 1 ) 1 . 8 3 ( 0 . 4 2 ) 
18:1 n-9 43.62(3.05)a 41.30(1.88f 38.55(1.93)。 
18:1n-7 3 . 0 7 (0.24) 2 . 7 5 (0.36) 2 . 7 2 (0.32) 
18:1 n-5 1.04 (0.33) 0.74 (0.24) 0.87 (0.32) 
20:1 n-7 0.61 ( 0 . 0 7 ) a 0.56 (0.07f 0.51 (0.10)。 
n-6 PUFA 
18:2 n-6 3.69 (0.80f 9.14 (2.29广 3.42 (0.76f 
20:2 n-6 0.06(0.023)b 0.10(0.02f 0.07 (0.01f 
20:3 n-6 0.08 {0.03f 0.11 (0.02f 0.03 (0.04)' 
20:4 n-6 0.34 {0.05f 0.36 (0.09)" 0.23 (0.05)' 
22:4 n-6 0.15(0.05) 0.18(0.15) 0.07 (0.09) 
22:5 n-6 0.26 (0.03f 0.25 (0.02f 0.30 (0.03)" 
n-3 PUFA 
22:6n-3 0.63 (0.12) 0.46 (0.14) 0.44 (0.10) 
CLA 
c-9, M1/N9, c-11-18:2n 0.16 (0.03)' 0.17 (0.10f 1.40 (0.19广 
c-10, M2/M0,c-12-18:2n 0 {Of 0 (Of 0.63 (0.12” 
^ 1 TG weight (mg I g) 7.34 (1.42)' 10.29 (3.30^ 10.42 (2.30^ 
Data are expressed as wt. % of total TG. 
Means at the same row with different superscripts C'^ '') differ significantly ^ K0.01) 
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Table 3.8 Effect of dietary C L A on hepatic phospholipid (PL) composition 
(Experiment 1) 
Fatty Acids CTL LA CLA 
Saturated fatty acids 
16:0 17.79 (0.80) 17.51 (1.15) 16.02 (2.59) 
18:0 18.95(1.17) 18.49 (2.54) 19.02(1.39) 
22:0 0.71 (0.39)a 0.24 (0.04)" 0.99 (0.29f 
M U F A 
16:1 n-9c 0.26(0.09)a 0.27 (0.09f 0.19(0.05f 
16:1 n-7c 1.04(0.14)a 0.80 (0.17)" 0.56(0.17)。 
18:1n-9 15.42 (0.90)" 13.36 (0.56)' 14.38 (0.98)" 
18:1n-7 2.20 (0.13)" 1 . 8 0 ( 0 . 5 0广 1 . 6 6 (0.23)" 
18:1rv5 1.82(0.16)b 0.22 (0.05f 0.21 (0.04)" 
n-6 PUFA 
18:2n-6 16.67 (0.71f 19.10(1.05)" 16.40(1.23)。 
20:2 n-6 0.47(0.03)b 0.53 (0.09f 0.63 (0.10f 
20:3 n-6 2.17(0.17) 1.94 (0.38) 2.31 (0.37) 
20:4 n-6 11.81 (0.83f 13.29(1.83)" 11.11 (1.52f 
22:4 n-6 0.21(0.13)b 0.32 (0.04f 0.37 (0.06)" 
22:5 n-6 1.27 (0.28f 1.39 (0.38f 2.27 (0.50f 
n-3 PUFA 
22:6n-3 7.15(0.85) 6.74(1.06) 6.23 (1.36) 
CLA 
c-9, M1/f-9, c-11-18:2n 0.00 (0.00)' 0.00 (O.OOf 0.69 (0.05f 
c-10，f-12/M 0,c-12-18:2n 0.00 (0.01 f 0.00 (0.00)' 0.42 (0.04” 
W a l PL weight (mg / g) 14.53 (1.52)' 16.79 (2.71 f 17.97 (1.99f 
Data are expressed as wt. % of total PL. 
Means at the same row with different superscripts (^' ^' ^) differ significantly (p<0.01) 
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Table 3.9 Effect of dietary C L A on hepatic phospholipid (PL) composition 
(Experiment 2). 
FaFty Acids CTL LA CLA 
Saturated fatty acids 
12:0 2.80(0.44)b 2.81 (0.65f 3.76 (0.23)" 
14:0 0.16(0.01)b 0.16(0.02)b o.13(0.02)" 
15:0 0.11 (0.02)b 0.10 (0.02)b 0.07 (0.03f 
16:0 15.79 (0.68)b 15.78 (0.50f 17.32 (0.60)" 
18:0 16.30 (0.52) 16.71 (1.15) 15.89 (0.77) 
22:0 1.55 (0.28)a 0.63 (0.19)。 1.14 (0.09f 
M U F A 
16:1 n-9c 0.36(0.05)a 0.31 {0.03f 0.27 (0.04)^  
16:1 n-7c 1.03 (0.22)" 0.78(0.18)" 0.70 {0A5f 
18:1n-9 15.84(1.26)a 12.15(0.93f 14.62(1.74f 
18:1 n-7 1.82 (0.16)a 1.64 (0.16f 1.51 (0.16f 
18:1 n-5 1.82 (0.16) 0.22 (0.05) 0 . 2 1 (0.04) 
20:1 n-7c 0.43 (0.05)^  0.41 (0.04)" 0.34 (0.05)" 
n-6 PUFA 
18:2n-6 12.25(0.84)c 16.10(0.81)" 13.79(0.87)" 
20:2 n-6 0.45 {0.05f 0.59 (0.07f 0.45 (0.09f 
20:3 n-6 2.29 {0.22f 2.50 (0.23” 2.26 {0.24)' 
20:4 n-6 12.42 (0.62)' 14.18 (0.69f 10.46 (0.58)。 
22:4 n-6 0.35 (0.04)' 0.44 (0.06)" 0.43 (0.06)^  
22:5 n-6 2.02 (0.52) 2.67 (0.78) 2.31 (0.73) 
n-3 PUFA 
22:6 n-3 8.03 (0.64f 6.79 (0.80)' 4.91 (0.88)。 
CLA 
c-9, M1/f-9, c-11-18:2n 0.14 (0.02f 0.11 (0.01)。 0.74 (0.07f 
c-10, M2/M0,c-12-18:2n 0.08 (0.01)' 0.04 (0.01)。 0.52 (0.04f 
1 ^ 1 PL weight (mg / g) 24.63(1.58)' 24.51 (1.06)' 26.12(1.07)^ 
Data are expressed as wt. % of total PL. 
Means at the same row with different superscripts f'^ '') differ significantly (p<O.Ol) 
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Figure 3.8 Hepatic cholesterol (mg / g) among the control, LA-supplemented and 
CLA-supplemented groups. The hamsters in experiment 1 were killed after 
ovemight fasting while the animals in experiment 2 were sacrificed without ovemight 
fasting. Data are expressed as means 土 SD of n=12 (Experiment 1) and n=10 
(Experiment 2). The significant difference is indicated as ** p<0.01. 
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3.5.4 Effect ofDietary CLA Supplementation on Adipose Tissue TG and 
Cholesterol 
Adipose tissue T G was lowered by dietary C L A supplementation, but it was 
only significant (p<0.05) in experiment 1 (Figure 3.9). Moreover, cis-9, trans-W-
and trans-lQ, cis-l2-CLA isomers were incorporated into adipose tissue TG. The 
fatty acid composition of T G was also changed (Tables 3.10 & 3.11). Similar to the 
hepatic TG, L A and its metabolites was increased apparently in the adipose tissue 
T G fraction, but that was not observed in the CLA-supplemented group. 
Unlike hepatic cholesterol, CLA-supplementation markedly increased the 
cholesterol level of adipose tissue by 34 % (Experiment 1) and average 33 % 
(Experiment 2) compared with the control group (Figure 3.10). 
3.5.5 Effect ofCLA Supplementation on Cholesterol Levels of Different 
Tissues 
Tissues from kidney, heart, brain and muscle (from adductor longus) were 
subjected to the cholesterol determination. Dietary C L A had neutral effect on the 
cholesterol level of kidney, heart and brain. However, muscle cholesterol level was 
significantly (p<0.05) reduced as compared with the control group (Table 3.12). 
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Figure 3.9 Adipose tissue triglyceride (TG) (mg / g) among the control, LA-
supplemented and CLA-supplemented groups. The hamsters in experiment 1 were 
killed after ovemight fasting while the animals in experiment 2 were sacrificed 
without ovemight fasting. Data are expressed as means 土 SD of n=12 (Experiment 1) 
and n=10 (Experiment 2). The significant difference is indicated as * p<0.05. 
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Table 3.10 Effect of dietary C L A supplementation on composition of perirenal 
adipose tissue triglyceride (TG) (Experiment 2). 
FatTy Acids CTL LA CLA 
Saturated fatty acids 
12:0 1.58 (0.10f 1.53 (0.06)" 1.35 {0.18)' 
14:0 0.56 (0.03)a 0.54 (0.02f 0.47 (0.03)。 
15:0 0.17(0.01)a 0.14(0.01)b 0.16(0.02)b 
16:0 13.95(1.91) 13.33(1.15) 16.32 (2.99) 
18:0 2.29 (0.44)b 2.29 (0.39f 3.23 (0.71 f 
M U F A 
16:1n-9c 0 . 7 7 ( 0 . 0 4 ) a 0.65 (0.03f 0.66 (0.07f 
16:1 n-7c 5.50 (0.60)" 4.66 (0.55f 3.52 (0.51)^  
18:1 n-9 57.35(1.71)a 49.36(1.13)^ 53.13(2.73” 
18:1 n-7 2.01 (1.51) 2.77 (0.12) 2.31 (1.08) 
18:1 n-5 0.31 (0.04) 0.24 (0.11) 0.39 (0.16) 
20:1 n-7c 0.48 (0.03) 0.44(0.04) 0.37(0.03) 
n-6 PUFA 
18:2 n-6 11.05 (0.72)' 19.96 {0.53f 8.69 (0.64)。 
20:2 n-6 0.09 (0.01f 0.11 (0.01f 0.01 (0.02)。 
CLA 
c-9, M1/f-9, c-11-18:2n 0.35 (0.03)' 0.30 (0.02)。 3.27 (0.26f 
c-10, f-12/M0,c-12-18:2n 0 (Of 0 (Of 1.82 (0.21f 
Total TG weight (mg I g) 800.10 (54.59) 828.65 (47.58) 770.81 (75.21) 
Data are expressed as wt. % of total TG. 
Means at the same row with different superscripts (^' ^' ^) differ significantly (^<0.01) 
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Table 3.11 Effect of dietary C L A supplementation on the composition of 
epididymal adipose tissue triglycerie (TG) (experiment 2). 
FatIy Acids CTL LA CLA 
Saturated fatty acids 
12:0 2.58 (0.10) 2.20 (0.68) 2.36 (0.22) 
14:0 0.56(0.02)a 0.53(0.02)b 0.49(0.06)。 
15:0 0.15(0.01)a 0.13(0.01)" 0.14(0.02)a 
16:0 18.76(1.75) 18.97(1.69) 19.70 (2.23) 
18:0 2.85 (0.27) 3.04 (0.41) 3.51 (0.67) 
M U F A 
16:1 n-9c 0.65 (0.05) 0.61 (0.04) 0.60 (0.08) 
16:1 n-7c 5.71 (0.54)" 5.22 (0.69)' 4.41(0.54)。 
18:1n-9 48.43(2.70)a 44.62(1.91f 48.55 (2.35)" 
18:1n-7 1.49(1.28) 0.73 (1.10) 1.43(1.24) 
18:1n-5 0.24(0.10) 0.22 (0.08) 0.26(0.17) 
20:1n-7c 0.38 (0.02)" 0.35 {0.02)' 0.34 (0.02)" 
n-6 PUFA 
18:2 n-6 12.64 (0.57f 18.75 (0.56f 10.63 (0.76)。 
20:2 n-6 0.10(0.01)b 0.11 (0.01)" 0.05(0.02)。 
20:3 n-6 0(0)b 0.016(0.019^ 0(0广 
20:4 n-6 0.02 (0.036f 0.058 (0.032f 0 (0)。 
CLA 
c-9, M1/f-9, c-11-18:2n 0.25 (0.02f 0.23 (0.01)。 2.24 (0.24)^  
c-10，M 2/f-10,c-12-18:2n 0 (Of 0 (Of 1.23 (0.20)" 
Total TG weight (mg / g) 774.51 (86.05) 739.33 (106.57) 748.47 (74.88) 
Data are expressed as wt. % of total TG. 
Means at the same row with different superscripts (^' ^' ^) differ significantly Q)<0.01) 
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Figure 3.10 Adipose tissue cholesterol (mg / g) among the control, LA-
supplemented and CLA-supplemented groups. The hamsters in experiment 1 were 
killed after ovemight fasting while the animals in experiment 2 were sacrificed 
without ovemight fasting. Data are expressed as means 土 SD ofn=12 (Experiment 1) 
and n=10 (Experiment 2). The significant difference is indicated as ** p<0.01. 
77 
Table 3.12 Effect of dietary C L A supplementation on cholesterol level of different 
tissues (Experiment 2) 
Cholesterol level (mg / g) 
Tissue type control (10)^  2 % L A (10) 2 % CLA(10) 
Kidney 4.00士0.15 4.04士0.15 3.93 士0.12 
Brain 16.46±3.25 17.18±3.82 17.65土3.58 
Heart 1.52±0.07 1.50±0.05 1.50土0.06 
Muscle (adductor longus) 0.37 土 0.02 0.34 士 0.03 0.35 土 O.Or 
1 Figures in parentheses indicate the number ofhamsters used, 
ap < 0.05 significantly different to the control group. 
Data are expressed as means 土 SD. 
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3.6 Discussion 
3.6.1 Effect of C L A Supplementation on Serum TG, TC and HDL-C 
In the present study, the animals were fed a hypercholesterolemic diet. 
Cholesterol levels of serum and liver were elevated markedly. From the study of 
Singhal et al. (1983), the diet containing cholesterol as low as 0.1% was sufficient to 
raise plasma cholesterol and it was confirmed by our present study. It was also 
found that dietary C L A and L A supplementation significantly reduced the fasting 
serum T G and TC. The results were in agreement with the previous observations 
on rabbit (Lee et al., 1994), hamster (Nicolosi et al., 1997) and mouse (Munday et al., 
1999) models. However, dietary C L A had no effect on the levels of T G and TC in 
the non-fasted hamsters. 
A number of studies have demonstrated the hypotriglyceridemic activity of L A 
and the related mechanism (Chait et al., 1974; Shimomura et al., 1990). However, 
there is still no explanation for the similar activity exerted by CLA. It is possible 
that C L A may act like L A and other PUFAs, and be able to increase solubility of 
lipids in the circulating lipoproteins and enhance the lipoprotein to lipoprotein lipase 
contact by increasing the unsaturation of the lipids (Engelberg, 1966). As a result, 
T G can be effectively removed from the bloodstream to peripheral tissues by 
increasing the activity of lipoprotein lipase. However, the reversal was observed in 
the study by Park et al. (1997) who showed that C L A in vitro reduced lipoprotein 
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lipase activity of mouse adipocytes. Thus, further investigations are necessary for 
the mechanism of hypotriglyceridemic activity exhibited by CLA. 
The mechanism by which L A lowers serum TC and non-HDL-C are poorly 
understood. Firstly, Spritz and Mishkel (1969) proposed that polyunsaturates would 
occupy more space within lipoprotein particles, resulting in lesser cholesteryl ester 
molecules residing in the core of LDL particles. Secondly, Vega et al. (1982) and 
Kuksis et al. (1982) demonstrated unequivocally that L A might reduce number of 
LDL particles by inhibition of hepatic synthesis of apoB-containing lipoproteins. 
V L D L is a TG-rich lipoprotein and responsible for T G transportation in circulation. 
Finally, it was suggested that L A might increase LDL-receptor activity, and, thus, 
enhance the fractional clearance rate for LDL in circulation (Grundy & Denke, 1990). 
For the perspective of CLA, it may reduce serum TC and non-HDL cholesterol via 
the same mechanism as in LA, In fact, it was recently found that trans-lO, cis-l2-
C L A isomer could significantly in vitro reduce apolipoprotein B secretion in HepG2 
cells in vitro (Yotsumoto et al,, 1999). 
HDL-C is regarded as "good" cholesterol. In the present study, both L A and 
C L A demonstrated neutral effects on serum HDL-C level. Moreover, L A and C L A 
could decrease the ratio of TC to HDL-C. This implies that L A and C L A may be 
anti-atherogenic, based on their favorable effect on serum lipid and lipoprotein 
profiles. 
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3.6.2 Effect of CLA Supplementation on Hepatic TG, PL and Cholesterol 
The present study showed that dietary C L A supplementation significantly 
increased the average liver weight in hamsters, as compared with that from the 
control and LA-supplemented groups. It is in agreement with the report of Moya-
Camarena et al. (1999). In their study, feeding C L A markedly increased liver 
weight and hepatic lipid content in rat. Furthermore, the present study 
demonstrated that dietary L A and C L A supplementation increased the hepatic T G 
levels, when the animals were killed without ovemight fasting (Experiment 2). As 
mentioned, T G rich in PUFAs may be a better substrate for lipoprotein lipase. 
Hence, the serum T G would be lowered. Also, PUFA-rich T G may be a better 
substrate for hepatic lipase, and the hepatic uptake of LA- and/or CLA-rich T G 
would be increased at the same time. As a result, feeding L A and C L A may 
significantly increase the hepatic T G levels. 
Feeding L A and C L A also altered the hepatic T G and PL composition. It is 
reasonable that L A (18:2n-6) and its metabolites (Figure 3.11), including y-linolenic 
acid (18:3n-6) and arachidonic acid (20:4n-6), were present at higher level in T G and 
PL fractions, when L A was supplemented in the diet. However, as the isomers of 
LA, C L A did not increase the levels of such fatty acids. On the contrary, L A 
(18:2n-6) and its metabolites (20:3n-6, 20:4n-6 and 22:4n-6) were found present at 
lower level in the CLA-supplemented group. This is in agreement with the finding 
from Belury and Kempa-Steczko (1997). C L A may compete with L A and oleic 
acid for the A6 desaturase which catalyses the rate-limiting step in the conversion of 
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Figure 3.11 Conversion of n-6 fatty acids to longer chain fatty acids, 
(adapted from Newton, 1996) 
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L A to arachidonic acid. Thus, the accumulation of L A and the metabolites in the 
T G and PL will be reduced by CLA. Also, C L A may undergo a metabolic pathway 
different from that ofLA. A number of novel fatty acids have been identified as the 
metabolites of CLA. These include 20:3A8,12,14, 20:4A5,8,12,14 and 
20:4A5,8,11,13 (Sebedio et al., 1997; Juaneda & S^edio, 1999). In addition, cis-
9, trans-W- and trans-lO, cis-l2-CLA isomers were incorporated predominantly into 
both hepatic T G and PL fractions in the present study. 
Finally, the present study demonstrated that dietary C L A supplementation 
showed a distinct hypocholesterolemic effect in the liver. The cholesterol level was 
decreased by 65% in experiment 1 and 29% in experiment 2. However, the 
mechanism involved remains poorly understood. Possibly, C L A may exert its 
cholesterol-lowering effect in the three ways, including effect on the endogenous 
synthesis of cholesterol, effect on the cholesterol transportation, and the effect on the 
absorption of exogenous cholesterol. This will be further discussed in chapter 4. 
3.6.3 Effect of CLA on Adipose Tissue T G and Cholesterol 
Dietary C L A supplementation could significantly reduce the total adipose tissue 
(perirenal + epididymal) weight in experiment 2. Similar observation was made in 
the studies ofBelury and Kempa-Steczko (1997), Park et al (1999) and DeLany et al. 
(1999), where mice and rats were used as animal models. Park et al (1997) found 
that C L A might inhibit fat storage in adipocytes coupled with elevated P-oxidation 
by elevating the activity of carnitine palmitotransferase in fat pads. Also, C L A 
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could affect hypertrophy and hyperplasia of fat cells by inhibiting both proliferation 
and differentiation of preadipocytes in animals (Brodie et al., 1999 & Satory and 
Smith, 1999). 
Dietary C L A or L A did not affect the adipose tissue (perirenal and epididymal) 
T G levels in experiment 2. However, similar to those in hepatic TG, a higher level 
of L A and its metabolites was observed in the LA-supplemented group, but not in the 
CLA-supplemented groups. Also, cis-9, trans-11 - and trans-lQ, cis-X2-CLA 
isomers were apparently incorporated into adipose tissue (perirenal and epididymal) 
TG. 
Dietary C L A significantly increased the cholesterol level in perirenal and 
epididymal adipose tissues. However, C L A had neutral effect on the cholesterol 
levels of other organs, including brain, kidney, heart and muscle (adductor longus). 
There is still no explanation for the cholesterol-raising effect of C L A in adipose 
tissue. Probably, since cholesterol is an essential molecule, a stable cholesterol 
level in different tissues is crucial. Therefore, in the present study, as the total 
adipose tissue weight was decreased, the amount of cholesterol per unit mass was 
increased correspondingly for the maintenance of a narrow stable cholesterol level. 
3.6.4 Implication of CLA Intake in Humans 
The present study showed that dietary C L A had a distinct hypolipidemic effect. 
C L A is, therefore, beneficial for the body fat control, cholesterol-lowering, and anti-
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atherogenesis. In our study, the dosage of C L A used was 2%. For a healthy male 
who weighs between 180 and 200 lbs., the food taken a day is probably 2000kcal. 
Therefore, 8 grams of C L A per day is necessary for a man to attain hypolipidemic 
effect, if humans respond similarly to hamsters. This apparently exceeds the 
estimated daily C L A intake of a normal person. The daily C L A intake per person is 
estimated as 1.5 grams at the present time (Scimeca, 1998). Eight grams of C L A 
per day may be difficult for a person to obtain from daily diet. However, according 
to the findings of Nicolosi et al. (1997), C L A intake as low as 0.06 en% and 0.11 
en% were able to exert anti-atherogenic and hypolipidemic effects in hamsters. If 
this concept is applied to humans, 0.06 en% and 0.11 en% of C L A are equivalent to 
0.13 g and 0.25 g of C L A per day, a level can be easily met from daily diet. 
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Chapter 4 
Influences of Dietary CLA on Cholesterol Homeostasis 
4.1 Introduction 
Cholesterol is an essential molecule for human. It is the precursor for the 
synthesis of biliary cholesterol, bile acids and steroid hormones (including 
progestagens, glucocorticods, mineralocorticoids, androgens, and estrogens). It can 
be taken up from exogenous sources or endogenous synthesis. Cholesterol is 
transported in plasma lipoprotein and stored in the liver in the form of cholesteryl 
ester. However, elevated serum cholesterol, especially LDL-cholesterol, is closely 
related to the risk of atherosclerosis and coronary heart disease (CHD). Therefore, 
cholesterol homeostasis is extremely important. 
Cholesterol homeostasis is maintained by a compensatory system including the 
levels of plasma lipids, lipoproteins, cholesterol absorption and synthesis, storage 
and fecal steroid excretion (Dietary & Wilson, 1970; Lin & Connor, 1980). To be 
specific, three basic mechanisms for cholesterol homeostasis are involved: (1) 
cholesterol synthesis is tightly regulated by the activity of hepatic 3-hydoxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA reductase); (2) cholesterol taken 
up from LDL is regulated by the number of LDL receptors in liver; (3) uptake of 
exogenous cholesterol is regulated predominantly by the intestinal A C A T (Goldstein 
&Brown, 1984). 
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The present results together with the others (Lee et al., 1994; Nicolosi et al., 
1997) showed that C L A had the distinct hypolipidemic effects. However, the 
mechanism involved remains unclear. It is hypothesized that dietary C L A may 
inhibit the hepatic H M G - C o A reductase activity (the rate-limiting enzyme in 
cholesterol synthesis) and the intestinal A C A T activity (the critical enzyme for 
intestinal absorption of exogenous cholesterol), and increase the fecal excretion of 
neutral sterols and/or acidic sterol. The present chapter is therefore to examine the 
effect of dietary C L A on H M G - C o A reductase, A C A T and fecal excretion of neutral 
sterols and acidic sterols. 
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4.2 Neutral Effect of Dietary C L A Supplementation on H M G - C o A reductase 
Activity 
4.2.1 H M G - C o A Reductase as the Rate-Limiting Enzyme in Cholesterol 
Synthesis 
Besides intake from exogenous sources, cholesterol can be synthesized 
according to the cellular cholesterol level. Cholesterol synthesis is a complex and 
energy-expensive reaction, and H M G - C o A reductase (EC 1.1.1.34) plays a 
regulatory role in the whole process (Brown et al., 1973). H M G - C o A reductase 
catalyzes the reduction of H M G - C o A to mevalonate, for which two molecules of 
N A D P H each donates two electrons and this is the rate-limiting step in the whole 
cholesterol synthesis (Brown et al., 1972 & 1974; Avigan et al., 1975). 
C〇〇-I 
C K I 2 
H3C—C—〇H P-Hydroxy-p-methylglutaryl-CoA 
CH, (HMG-CoA) 
I 2 zJZ\ 〇z ^S-CoA 
^ 2 N A D P H + 2H+ 
H M G - C o A ^ ^ _ _ ^ 
^ ~ ^ 2NADP+ 
reductase 
^ ~ • CoA-SH y 
c〇〇-I 
CH, I 2 
H C—C—OH Mevalonate 
3 I 
严2 
C H ^ H 
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H M G - C o A reductase is synthesized at the membrane-bound ribosome (Brown 
& &moni, 1984) and accumulated at the endoplasmic reticulum (Goldstein & Brown, 
1984). It is found that the molecular weight of H M G - C o A reductase is around 
51,000 士 1,800 daltons by SDS gel electrophoresis (Beg & Brewer, 198¾. H M G -
CoA reductase is rich in liver and exhibits a very short half-life of 2 to 4 hours 
(Heller & Shrewsbury，1976). 
H M G - C o A reductase activity is regulated by intracellular cholesterol level, as 
well as hormonal controls. As L D L carries cholesterol into cell, the number of 
L D L receptors and intracellular cholesterol level increase, and this leads to the down-
regulation of H M G - C o A reductase (Brown & Goldstein, 1986). Hormonal controls 
include stimulation by insulin and inhibition by glucagon. There are two types of 
regulation: instant and long-term effects. Rapid regulation includes modification by 
isosteric and allosteric effectors and by covalent modification. For the isosteric and 
allosteric regulation, derivatives of cholesterol and key intermediate mevalonate can 
inhibit H M G - C o A reductase activity. For the covalent modification, a bicyclic 
cascade system involving phosphorylation-dephosphorylation is proposed (Brown et 
al., 1979; Beg & Brewer, 1982). The enzyme is being active in the 
dephosphorylated form and is promoted by insulin. On the other hand, glucagon 
stimulates phosphorylation of the enzyme and H M G - C o A reductase activity is 
inhibited. The long-term effect of H M G - C o A reductase is achieved by reduction in 
enzyme concentration by modulation of enzyme synthesis and/or degradation. 
Cholesterol and metabolites derived from mevalonate can exert the inhibition by 
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controlling the transcription and translation of the enzyme. Also, sterols can 
accelerate the degradation ofHMG-CoA reductase (Goldstein & Brown，1990). 
Since H M G - C o A reductase is critical in cholesterogenesis and the inhibition of 
this enzyme may be the best approach to the regulation of cholesterol biosynthesis. 
In fact, a number of H M G - C o A reductase inhibitors are developed, like lovastatin, 
mevinolin, pravastatin, and compactin from fungus Penicillium citrinum (Fears et al., 
1980; Endo, 1992). At the same time, some of these H M G - C o A reductase 
inhibitors have been applied for clinical use (West of Scotland Coronary Prevention 
Study Group, 1998). 
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4.2.2 Objective of the Present Study 
It was previously demonstrated that dietary C L A supplementation reduced the 
hepatic cholesterol, serum total and non-HDL cholesterol levels. Moreover, H M G -
CoA reductase is a critical enzyme in cholesterol synthesis. Therefore, the 
objective of the present study was to examine the effect of dietary C L A 
supplementation on the activity ofhepatic H M G - C o A reductase in vivo. 
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4.2.3 Materials and Methods 
H M G - C o A reductase activity was measured according to Erickson et al. (1977) 
and Edwards et al. (1979) with some modifications. 
4.2.3.1 Preparation of Hepatic Microsome 
Liver samples (2 g) were homogenized in 8 ml homogenizing buffer (pH 7.2), 
containing 0.1 M sucrose, 0.05 M KC1, 0.03 M E D T A and 0.04 M KH2PO4, using 
glass Potter-Elvehjem homogenizer with Telfon pestle. The homogenate was 
centrifuged at 12,000 g for 10 min. After removal of the fat layer, the supernatant 
was collected. The pellet was resuspended in 8 ml homogenized buffer and 
centrifuged at 12,000 g for another 10 min. All the supematants from the above 
centrifugations were then centrifuged at 105,000 g for 70 min. The final pellet was 
resuspended by gentle homogenization in homogenizing buffer and the protein 
content was determined by method of Lowry et al. (1951). 
4.2.3.2 HMG-CoA Reductase Activity Assay 
For each assay, 800 jag microsomal protein was mixed with assay buffer (pH 
7.2), containing homogenizing buffer, 54 m M dithiothreitol (DTT), G6PDH (40 units 
/ ml), 162 m M G6P, and 16.2 m M NADP. The reaction mixture was pre-incubated 
at 37。C with shaking for 20 min. The reaction was initiated by addition of H M G -
CoA, DL-3-[glutaiyl-3-"C]- (from N E N ™ , M A ) with 1 Ci / mol. The mixture was 
then incubated at 37。C for 60 min. The reaction was stopped with 5 N HC1 and 
mevalonolactone, RS-[5-^N)]- (from N E N ™ , MA) with 10 jaCi / ml was added as 
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the internal standard. The final mixture was incubated at 2>TC for further 30 min. 
The precipitated protein was removed by centrifugation and the supernatant was 
applied to an AGl-X8 fromate column (0.7 x 10 cm, from Bio-Rad) made up in 
water. The sample was then eluted with water. The first 500 i^l was discarded, 
and the mevalonolactone was collected in the next 3 ml fraction. The collected 
eluate was mixed with 10 ml liquid scintillation fluid (OptiPhase 'HiSafe" 3 
universal scintillation cocktail) for scintillation counting. Assays preformed in the 
absence of microsomal protein gave background values which were subtracted from 
experimental values. 
4.2.4 Statistics 
H M G - C o A reductase activity was expressed as pmol of mevalonate formed per 
min per m g protein. Results were expressed as means 士 SD. One way analysis of 
variance (ANOVA) and Student's "test were employed for statistical analysis. 
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4.2.5 Results 
Similar H M G - C o A activities were observed in both the control, LA-
supplemented and CLA-supplemented groups (Figure 4.1). In the experiment 1, the 
H M G - C o A reductase activity of CTL, L A and C L A groups was 13.82 士 1.71, 13.64 
土 1.87, 13.37 士 1.55 respectively. In experiment 2, the H M G - C o A reductase 
activity (pmole / min / m g protein) of CTL, L A and C L A groups was 20.25 士 3.56, 
20.39 士 2.64, and 20.31 士 3.74 respectively. The value for time zero control ofthe 
three groups in experiment 1 was 4.90 pmole / min / m g protein and that in 
experiment 2 was 4.54 pmole / min / m g protein. There was no significant 
difference among the three groups in both experiments 1 and 2. It was noticed that 
the H M G - C o A reductase activity in the hamsters without ovemight fasting 
(Experiment 2) was significantly higher than that of the hamsters which were killed 
after ovemight fasting (Experiment 1). 
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Experiment 1 Experiment 2 
Figure 4.1 Effect of dietary L A and C L A supplementation on hepatic H M G - C o A 
reductase activity. Data are expressed as means 土 SD ofn=12 (Experiment 1) and 
n=10 (Experiment 2). 
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4.2.6 Discussion 
The H M G - C o A reductase activity in the present study was detected at relatively 
low level. This is probably due to the feeding of a high-cholesterol diet. It has 
been demonstrated that dietary cholesterol could efficiently down-regulate the de 
novo cholesterol synthesis and inhibit H M G - C o A reductase activity in rats, hamsters 
and rabbits (Kovanen et aL, 1978; Roach et al., 1993). Addition of cholesterol 
(O.50/0 or 1%) to the chow diet could lower hepatic microsomal H M G - C o A reductase 
activity by 90% (Singhal et aL, 1983). Since dietary cholesterol increases hepatic 
LDL receptor activity, more cholesterol is transferred to the liver, feedback inhibition 
by dietary cholesterol and its derivatives is expected (Brown & Goldstein, 1986). 
The present results also suggested that H M G - C o A reductase activity in hamsters is 
much lower than that in other species. For example, from the study ofBrown et aL 
(1979), the hepatic H M G - C o A reductase activity from hypercholesterolemic rats was 
a few hundred pmol / min / mg protein. 
Field et al. (1987) reported that polyunsaturated fatty acid (PUFA) was able to 
modulate the H M G - C o A reductase activity. However, the present experiment 
found that neither L A nor C L A could affect the H M G - C o A reductase activity. This 
is probably due to the intrinsically low cholesterol synthesis rate in hamsters (as 
described in section 3.4) and feedback inhibition induced by a high cholesterol diet. 
Thus, the effect of CLA on HMG-CoA reductase may not be significant under the 
present experimental conditions. 
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4.3 Down-Regulation of the Intestinal A C A T Activity by C L A Feeding 
4.3.1 Role of A C A T in Cholesterol Absorption 
A C A T (EC 2.3.1.26) is responsible for the intracellular esterification of 
cholesterol. The presence of A C A T is identified in different animal species like rat, 
guinea pig, rabbit, hamster and human (Haugen & N o m m , 1976). This enzyme 
catalyzes the transfer of a fatty acid from coenzyme A to the hydroxyl group of 
cholesterol, resulting in formation of cholesteryl ester. The enzymatic activity is 
affected by not only the amount of microsomal cholesterol, but also an extra-
microsomal soluble protein such as lipoprotein, especially intermediate density 
lipoprotein (IDL) (Sano et al., 1985). 
^ / ^ ^ ^ ^ ^ 
r ^ ^ K ^ 
^ ^ ^ p ^ ^ ^ Cholesterol 
H 〇 A ^ ^ W ^ 
Z ^ Fatty acyl-CoA 
Acyl-CoA-cholesterol / 
acyl transferase 
(ACAT) V ^ CoA-SH 
^ T ^ ^ ^ 
i ^ " ^ K S 
〇 r ^ ^ k ^ ^ 丄 \ Cholesteryl ester 
R A 〇 ^ ^ ^ 
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A C A T plays an important role in the intestinal cholesterol absorption (Helgemd 
et al., 1982). Cholesterol is absorbed and internalized into the mucosal cells as free 
form, but is esterified predominantly by the time it reaches the lymph (Shiratori & 
Goodman, 1965). It is believed that more than 90% of the absorbed cholesterol is 
excreted into mesenteric lymph as cholesteryl ester. The site with the greatest 
A C A T activity is jejunum, which is the major site of cholesterol absorption. 
Since hypercholesterolemia is positively related to the risk of atherosclerosis 
and coronary vascular disease, controlling A C A T activity may be an alternative way 
to regulate the serum cholesterol level. In fact, there is a number of A C A T 
inhibitors available, like CL277,082 (Largis et al. 1989), HL-004 (Murakami et aL, 
1994) and 57-118 (Heider et al., 1983). 
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4.3.2 Objective of the Present Study 
The previous experiment found that dietary C L A possessed significant 
hypocholesterolemic effect. It was also demonstrated that C L A had neutral effect 
on the activity of hepatic H M G - C o A reductase. The objective of the present study 
was to examine the effect of dietary C L A on the activity ofintestinal ACAT. 
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4.3.3 Materials and Methods 
The A C A T activity was determined as described previously by Murakami et al 
(1994) with little modification. 
4.3.3.1 Preparation of Intestinal Microsome 
Microsomal fraction containing A C A T was prepared from the small intestine of 
the golden Syrian hamsters from experiment 2. When the hamsters were killed, the 
first 10 cm of intestine from the stomach was removed and discarded. The next 30 
cm was collected and placed on ice immediately. The intestine was incised 
longitudinally and washed with excess cold saline. The mucosal layer of intestine 
was scraped off with surgical knife, and the preparation was then placed in phosphate 
buffer (pH 7.4). 
Intestinal microsomes were then prepared from the mucosa as described in 
section 4.2.3.1. The final preparations were stored at -70°C until use. 
4.3.3.2 ACAT Activity Assay 
For each assay, 200 i^g of microsomal protein was mixed with 100 m M 
potassium phosphate buffer adjusted to pH 7.4 and 200 ^ ig of fatty acid-free bovine 
serum albumin (from Sigma, MA). The reaction mixture was pre-incubated at 37°C 
for 5 min. Reaction was initiated by adding 5 nmole of oleoyl coenzyme A, 
[oleoyl-l-'^ C]- (from N E N ™ , M A ) with activity 5 ^ iCi / ml. The reaction mixture 
was incubated for additional 6 min. The reaction was stopped by adding 5 ml of 
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chloroform-methanol (2:1, v/ v). After 1 ml 0.04 N HC1 and 20 ^1 of cholesteryl 
oleate, [cholesteryl-l,2,6,7-^N)]- (from N E N ™ , M A ) with activity 10 i^Ci / ml 
were added, the samples were vortexed, and then centrifoged at 2,000 g for 30 min. 
The chloroform phase was taken to dryness under nitrogen stream. The samples 
were dissolved in 50 jul chloroform containing unlabelled cholesteryl oleate (from 
Sigma, MA), and spotted on a thin-layer chromatography plate (Kieselgel 60 F254, 
Merck). The cholesteryl esters were separated in hexane-diethyl ether-acetic acid 
(80:20:1, v/ v/ V) , and exposed to iodine vapor for identification. The band 
corresponding to cholesteryl oleate was scraped and added into liquid scintillation 
fluid for scintillation counting. 
4.3.4 Statistics 
A C A T activity was expressed as pmol of cholesteryl oleate formed per min per 
mg protein. Results were expressed as means 土 SD. One way A N O V A and 
Student's Mest were used for statistical analysis. Difference was considered 
significant when p value was less than 0.05. 
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4.3.5 Results 
There was a significant difference in the intestinal A C A T activities among the 
control, LA-supplemented and CLA-supplemented groups. The A C A T activity of 
CLA-supplemented group was decreased up to 58% (p<0.05), as compared to those 
ofLA group and CTL group. However, L A group and CTL group had similar level 
of intestinal A C A T activity (Figure 4.2). The A C A T activity of the time zero 
control was 1.39 士 0.01 pmole / min / m g protein. 
I 
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Figure 4.2 Effect of dietary C L A supplementation on the intestinal A C A T activity 
(Experiment 2). Data are expressed as means 土 SD of n=10. Significant 
difference is indicated by * p<0.05. 
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4.3.6 Discussion 
The intestine samples were obtained from the hamsters, which were killed 
without overnight fasting (full stomach). It is because A C A T activity in the fasted 
animal is lower than that in fed animal (Helgemd et al., 1982). The present study 
showed that C L A supplementation could apparently suppress the intestinal A C A T 
activity. To m y best of knowledge, this is the first time to show that C L A 
supplementation can down-regulate the intestinal absorption of cholesterol. 
However, the mechanism by which C L A inhibits the intestinal A C A T activity is still 
unclear at the present time. 
One of the possible hypotheses is that, similar to other A C A T inhibitors, C L A 
may act on the enzyme by the inhibition of cholesterol solubilization in the micelles 
in the gut (Heider et al., 1983). Because of the steric and spatial difference 
compared with that ofLA, C L A may reduce the hydrophobicity ofmicelles and thus 
less free cholesterol is wrapped. In this way, less free cholesterol is internalized 
into intestinal mucosal cells and less substrate is accessible for the esterification 
taken by ACAT. As a result, the overall intestinal A C A T is less expressed. In the 
control and LA-supplemented groups, since the internalization of free cholesterol 
was not reduced and there was sufficient or even excess free cholesterol available, 
more intestinal ACAT induced and expressed. Another possible mechanism is that 
C L A may form a non-absorbable complex with cholesterol. As a result, this leads 
to the inhibition of cholesterol uptake at the absorptive site, possibly at the brush-
border membrane, resulting in the lowering of cholesterol esterification, inhibitory 
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effect ofACAT activity and chylomicrons formation in the intestinal mucosal cell. 
Unlike other synthetic A C A T inhibitors (CL277,082, HL-004, and 57-118), 
C L A is a naturally occurring fatty acid. Also, it is not as bulky as other artificial 
A C A T inhibitors. However, its application as hypocholesterolemic agent remains to 
be confirmed by further studies. In order to reinforce the hypothesis that C L A 
decreases cholesterol absorption, the fecal excretion of neutral sterols and bile acids 
was examined in the hamsters fed a diet supplemented with 2 % CLA. 
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4.4 Alteration of Fecal Excretion by Dietary C L A 
As mentioned, small intestine plays an important role in cholesterol homeostasis. 
The absorption of dietary cholesterol takes place from the luminal site of the small 
intestine. Absorbed cholesterol is then esterified to cholesteryl ester by intestinal 
ACAT, and transported as chylomicron to the lymph duct and then to the circulation. 
However, the absorption efficiency of dietary cholesterol appears to be roughly 50 % 
(Grundy, 1983). In other words, almost half of the amount of dietary cholesterol 
would be excreted as cholesterol or its microbial-derived forms directly in feces. 
For the endogenous cholesterol, excretion from the liver into the bile, either 
directly in nonesterified form or after the conversion to the more polar bile acids, is 
the major excretion of cholesterol from the body. Furthermore, apart from the 
minor amounts of sterols being lost from the skin or into the urine as steroid 
hormones, or from the sloughing of mucosal cells into the intestinal lumen, biliary 
excretion represents the only possibility for net elimination ofendogenous sterol. 
Therefore, quantification of neutral and acidic sterols in feces offers an 
alternative way to understanding cholesterol metabolism in the body. Also, it is 
able to provide crucial data for the "cholesterol-balance study" (Connor et al., 1969). 
Though some investigators hold that fecal neutral and acidic sterol analysis may be 
inconclusive sometimes (Gmndy, 1975), it still provides important information on 
the physiological regulation of cholesterol and bile acid synthesis for understanding 
cholesterol homeostasis under various experimental conditions. Moreover, 
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coupling with other assays, like H M G - C o A reductase and A C A T activity assays, 
possible mechanisms for the changes in cholesterol can be illustrated and predicted. 
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4.4.1 Objective of The Present Study 
As described in section 4.3, C L A supplementation could inhibit intestinal 
A C A T activity in vivo. Since A C A T is a critical enzyme for cholesterol absorption, 
it is hypothesized that C L A may alter the excretion of cholesterol and/or its 
derivatives at the same time. Also, it was worthy to study the effect of C L A on bile 
acid metabolism. Therefore, the objective of this study was to determine 
quantitatively the fecal excretion of neutral and acidic sterols, during the 8-week 
feeding of L A and C L A supplementations. 
I 
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4.4.2 Materials and Methods 
The fecal neutral and acidic sterols were determined according to Czubayko et 
aL (1991) with some modifications. 
4.4.2.1 Separation of Neutral and Acidic Sterols 
Fecal samples were first dried in a lyophilizer for 3 days and then ground. 
Stigmasterol (0.3 m g in 1 ml chloroform) and hyodeoxycholic acid (0.3 m g in 1 ml 1 
N NaOH) were added to 300 m g ground fecal sample as internal standards for 
neutral and acidic sterols, respectively. The samples were then subjected for 
alkaline hydrolysis with 8 ml lN N a O H in 90% ethanol at 90。C for 1 hour followed 
by cooling down to room temperature. One ml of distilled water and 8 ml of 
cyclohexane were added for extraction. After centrifugation, the upper cyclohexane 
phase and the lower aqueous phase were collected for neutral and acidic analyses, 
respectively. 
4.4.2.2 Neutral Sterol Analysis 
The cyclohexane phase was evaporated to dryness under a gentle nitrogen 
stream. The neutral sterols were then converted to their TMS-ether derivatives by 
adding TMS-reagent (Sil-A reagent, Sigma) and heated at 60。C for 1 hour. The 
mixture was then dried under nitrogen stream and the TMS-derivatives of neutral 
sterols were dissolved in 400 jul of hexane. After centrifugation, the hexane layer 
was transferred to a vial for GLC analysis. 
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4.4.2.3 Acidic Sterol Analysis 
One ml of 10 N N a O H was added to the lower aqueous phase and the mixture 
was heated for 3 hours at 120。C. After addition of3 ml distilled water and cooling 
to room temperature, the samples were acidified to pH < 1 with 25 % HC1, and the 
acidic sterols were extracted twice with 7 ml diethyl ether. The combined ether 
phases were evaporated under nitrogen stream. Methylation was performed by 
adding 2 ml dried methanol, 2 ml dimethoxypropane, and 40 jul concentrated HC1. 
The samples were mixed thoroughly and allowed to stand at room temperature for 
ovemight. The acidic sterols were then dried under nitrogen stream and converted 
to their TMS-ether derivatives as described for neutral sterol. The dried samples 
were dissolved in 300 i^l hexane and, after centrifugation, the hexane phase was 
transferred to vials for G L C analysis. 
4.4.2.4 G L C Analysis of Neutral and Acidic Sterols 
The G L C of fecal neutral and acidic sterols was carried out on a fused silica 
capillary column as described in section 3.3.6. For the neutral sterols, the column 
temperature was programmed at 285。C and maintained for 30 min. For the acidic 
sterols，the column temperature was programmed at 230 to 280。C at a rate of r C 1 
min. Helium was used as the carrier gas at a head pressure of 22 psi in both neutral 
and acidic sterol GLC. Typical chromatograms of neutral sterols and acidic sterols 
were shown in Figure 4.3 and Figure 4.4, respectively. 
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Figure 4.3 Typical gas liquid chromatographic profile of fecal neutral sterols. 
Identification of peaks: 1, coprostanol; 2, coprostanone; 3, cholesterol; 4, 
dihydrocholesterol; 5’ campersterol; 6’ intemal standard (stigmasterol); 7, p~ 
sitosterol; 8, stigmastanol. See text for the conditions ofseparation. 
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Figure 4.4 Typical gas liquid chromatographic profile of fecal acidic sterols. 
Identification of peaks: 1, lithocholic acid; 2, deoxycholic acid; 3, cholic acid; 4, 
internal standard (hyodeoxycholic acid); 5, ursodeoxycholic acid. See text for the 
conditions of separation. 
112 
4.4.3 Statistics 
Neutral and acidic sterols are expressed in m g per gram feces. Data are 
expressed as mean 士 standard deviation (SD). Data were statistically analyzed 
using one-way A N O V A and Student's /-test. Difference was considered significant 
when p value was less than 0.01. 
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4.4.4 Results 
4.4.4.1 Effect of C L A Supplementation on Fecal Output of Neutral Sterols 
Fecal neutral sterols were separated and quantified by GLC. The neutral 
sterols included coprostanol, coprostanone, cholesterol, dihydrocholesterol, 
campesterol, stigmasterol (internal standard), p_sitosterol and stigmastanol (Figure 
4.3). 
In both experiment 1 and experiment 2, the total fecal neutral sterols were 
significantly increased in the CLA-supplemented groups, as compared to the control 
and LA-supplemented groups (Figure 4.5). In experiment 1, the increased excretion 
of neutral sterols was observed in CLA-supplemented group after week 2. In 
experiment 2, the increment of neutral sterol excretion was found in the whole 
feeding period. Also, the composition of fecal neutral sterols was also altered, but 
no conclusive pattern could be found. Moreover, the fecal excretion of neutral 
sterols in experiment 1 was larger than that in experiment 2. 
4.4.4.2 Effect of CLA Supplementation on Fecal Acidic Sterols 
Different acidic sterols, including lithocholic acid, deoxycholic acid, cholic acid, 
hyodeoxycholic acid (internal standard) and ursodeoxycholic acid were well-
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C L A supplementation did not affect the fecal excretion of acidic sterols in both 
experiment 1 and experiment 2, as compared to the control and LA-supplemented 
groups (Figure 4.6). There was no evidence to show that CLA-supplementation 
would change the pattem of acidic sterol excretion. Moreover, the fecal excretion 
of acidic sterols in experiment 2 was apparently larger than that in experiment 1. 
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The present results showed that dietary supplementation generally increased the 
fecal excretion of neutral sterols. As the isomeric forms of LA, C L A was more 
effective in enhancement of neutral sterol excretion. The different neutral sterols 
identified in feces were possibly the products of the bacterial modification of 
cholesterol in gut (Figure 4.7) (Kellogg, 1974). These fecal neutral sterols are 
capable to diminish the intestinal cholesterol absorption, by which they lower the 
capacity of micells and displace cholesterol from micellar binding during absorption 
(Hassan & Rampone, 1979; Ikeda & Sugano, 1983; Heimann et al., 1991) 
Quantitatively, most important bile acids formed in mammalian bile are cholic 
acid, chenodeoxycholic acid, and deoxycholic acid (secondary bile acid). Small 
amounts of ursodeoxycholic acid and lithocholic acid (secondary bile acid) are also 
present (Figure 4.8) (Einarsson & Angelin, 1986). In the present study, all ofthese 
bile acids were found in the feces of hamsters from the control, LA-supplemented 
and CLA-supplemented groups. Moreover, the amount of acidic sterols were 
apparently smaller than that of neutral sterols. Most probably, the bile acids are 
very efficiently (95%-98%) reabsorbed from the intestine, mainly by an active 
process in the distal ileum (Einarsson & Angelin, 1986). 
Incomplete intestinal absorption of dietary cholesterol may be one of the 
possible mechanisms against overloading effect of dietary cholesterol in blood. 
Since C L A can down-regulate the ACAT activity and, therefore, it is hypothesized 
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Figure 4.7 Structures of native cholesterol and its microbial-derived sterols 
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Figure 4.8 Structure of some common bile acids 
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that C L A may interfere the absorption of cholesterol. In fact, C L A supplementation 
could significantly increase excretion of total fecal neutral sterol, but have a neutral 
effect on the production of total fecal acidic sterol. 
The mechanisms by which dietary C L A decreases the absorption of cholesterol 
may be one or combination of the following possibilities. Firstly, C L A may affect 
the internalization of dietary cholesterol from the intestine by (i) reducing the 
micellar solubility of cholesterol; (ii) inhibiting cholesterol uptake in the absorptive 
site, possibly at the brush-border membrane; or (iii) forming non-absorbable complex 
with cholesterol in the intestine lumen. In this way, less free cholesterol is available 
for the esterification taken by A C A T in the intestinal mucosal layer. A C A T activity 
is then reduced because of the lack of induction by the substrates. Secondly, at the 
same time，more free cholesterol is available for bacterial modification in large 
intestine, resulting in the increase of microbial-derived cholesterol metabolites. 
Because of the discrimination of sterol absorption, these cholesterol derivatives 
would not be absorbed (Ikeda & Sugano, 1983). As a result, excretion of fecal 
neutral sterols, including cholesterol and its derivatives, would be increased. 
Thirdly, since less dietary cholesterol is absorbed, the turnover rate ofbile acids from 
cholesterol is not necessary to be increased. C L A supplementation may lower the 
plasma total cholesterol level and hepatic cholesterol level via the proposed 
mechanisms summarized in Figure 4.9. 
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C L A has been extensively studied since the last decade. Probably, it is due to 
the unusual native conjugated diene structure, its distinct animal origin, and its 
unique biological effects. Many studies have demonstrated hat C L A has a wide 
range of physiological activities, including being anticarcinogenic, antiatherogenic, 
hypolipidemic, antioxidant and immuno-modulatory (Steunhart, 1996). 
In the present study, the effect of C L A on LDL oxidation was examined in vitro. 
C L A (in 1.5 ^iM BSA) showed a strong protective effect against Cu^^-mediated 
human LDL oxidation in a dose-dependent manner (2.5 m M to 20 mM), while L A 
showed a pro-oxidant effect on LDL oxidation. This is the first report 
demonstrating the in vitro protective effect of C L A against human LDL oxidation. 
The possible mechansim for the antioxidant effect of C L A on LDL oxidation may be 
due to the transformation of conjugated diene to a p_hydroxy acrolein moiety, which 
can chelate metal ions and interrupt Fenton reaction. C L A may also facilitate the 
formation of Cu^7BSA complex, in which Cu^+is unable to initiate LDL oxidation. 
A large number of studies have reported oxidative modification of LDL plays a 
crucial role in atherogenesis (Jiala & Devaraj, 1996; Hamilton, 1997; Steinberg, 
1997; Holvoet & Collen, 1998; Nielsen, 1999). The protective effect of CLA 
against LDL oxidation suggests that consumption of C L A may lower the risk for 
CHD. 
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The hypolipidemic effect of C L A was also demonstrated in the present study. 
C L A and L A supplementation could significantly reduce the semm TG, TC and non-
H D L cholesterol. C L A supplementation also showed a distinct lowering effect on 
hepatic cholesterol. C L A decreases serum T G level probably via the similar 
mechanism of LA. Perhaps, C L A may also increase lipoprotein lipase activity and 
enhance the clearance of serum T G (Chait et aL, 1974; Shimomura et al., 1990). 
The present study examined the possible mechanisms by which C L A 
supplementation decreases the serum cholesterol and hepatic cholesterol. Dietary 
C L A supplementation exhibited neutral effect on H M G - C o A reductase, the rate-
limiting enzyme in cholesterol synthesis. However, intestinal A C A T activity was 
down-regulated by C L A supplementation. A C A T is a critical enzyme in cholesterol 
esterification and absorption. This was in agreement with the observation that 
dietary C L A increased the fecal excretion of neutral sterols, but it had no effect on 
fecal acidic sterols. It is most likely that C L A may induce malabsorption and affect 
intestine transit of cholesterol at the small intestine. This leads to an increase in 
free cholesterol in intestinal lumen and bacterial modification of cholesterol. As a 
result, fecal excretion ofhigh level of neutral sterols is expected. 
In order to elevate the semm TG and cholesterol to a level similar to human, a 
high-fat and high-cholesterol diet was used in the present study. The present results 
in hamsters, although not directly applicable to humans, may have some implications 
for individuais who often consume a high-fat and high-cholesterol diet. The 
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reduction in serum fasting T G and cholesterol by dietary C L A supplementation is not 
associated with the inhibition ofhepatic H M G - C o A reductase activity, but it is most 
likely mediated by its inhibitory effect on cholesterol absorption via the down-
regulation of intestinal A C A T activity. If C L A consumption in humans is 
associated with a significant decrease in the risk of CHD, part of the mechanism may 
involve the protection of LDL against oxidative modification by C L A in addition to 
its hypolipidemic activity. 
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